

DEPARTMENT OF ONCOLOGY PUBLICATIONS 2012

Bassam Abdulkarim

1. L. Capelle, M. McKenzie, K. Joseph, N. Pervez, K. Tankel, Z. Gabos, J. Amanie, S. Chafe, **B. Abdulkarim**. Skin Sparing Helical Tomotherapy versus 3D Conformal Radiotherapy for Adjuvant Breast Radiotherapy – a Randomized Controlled Trial. Preliminary analysis of 90 patients. *Int J Radiat Oncol Biol Phys*. 2012 Aug 1;83(5):e583-90.
2. Manik Chahal, **Bassam Abdulkarim**, Yaoxian Xu, Marie-Christine Guiot, Jacob C. Easaw, Nicolas Stifani and Siham Sabri. O⁶-Methylguanine-DNA Methyltransferase is a Novel Negative Effector of Invasion in Glioblastoma Multiforme. *Mol Cancer Ther*. 2012 Nov;11:2440-50. Epub 2012 Sep 17. **Siham Sabri and Bassam Abdulkarim contributed equally to this work.**

Moulay Alaoui-Jamali

1. da Silva SD, Hier M, Mlynarek A, Kowalski LP, **Alaoui-Jamali MA**. Recurrent oral cancer: current and emerging therapeutic approaches. *Front Pharmacol*. 2012;3:149. doi: 10.3389/fphar.2012.00149. (Review)
2. Garcia AG, Nedev H, Bijian K, Su J, **Alaoui-Jamali MA**, Saragovi HU. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. *Oncogene*. 2012 Jul 16. doi: 10.1038/onc.2012.283.
3. Valentin MD, da Silva SD, Privat M, **Alaoui-Jamali M**, Bignon YJ. Molecular insights on basal-like breast cancer. *Breast Cancer Res Treat*. 2012 Jul;134(1):21-30. (Review)
4. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, **Alaoui-Jamali MA**. Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases. *Eur J Med Chem*. 2012 Feb;48:143-52.

Books and Book Chapters

1. “Advances in DNA Repair in Cancer Therapy (Second edition)”, Series: Cancer Drug Discovery and Development. Editors: L Panasci, A. Raquel and **MA Alaoui-Jamali**, Humana Press, 2012 (BOOK).
2. **Alaoui-Jamali MA**, Saad A, and Batist G. Integration of inhibitors of DNA damage-activated signaling for potentiation of chemotherapy response in refractory cancers, In “DNA Repair in Cancer Therapy (Second edition)”, Editors: L Panasci, A. Raquel and MA Alaoui-Jamali, Humana Press, 2012 (BOOK CHAPTER).

Thierry Alcindor

1. Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, **Alcindor T**, Vuong T. EGFR and K-ras gene mutation status in Squamous Cell Anal Carcinoma: A Role for Concurrent Radiation and EGFR Inhibitors? *British Journal of Cancer*. 2012 Nov 20;107(11):1864-8. doi: 10.1038/bjc.2012.479. Epub 2012 Oct 23.
2. *Abu-Sanad, A, Warsi A, Michel RP, Nahal A, Popradi G, Storrington JM, Liberman AS, **Alcindor T**. Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma. *Current Oncology*. 2012 Aug; 19(4):e289-91. doi: 10.3747/co.19.964

3. Hanna WC, Roberge D, David M, Waschke KA, Sudarshan M, Mayrand S, **Alcindor T**, Ferri LE. What is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer? *Current Oncology*. 2012 Apr;19(2):e60-6
4. Ferri LE, Ades S, **Alcindor T**, Chasen M, Hickeson M, Artho G, Marcus V, Thirlwell MP. Peri-Operative Docetaxel, Cisplatin, and 5-Flourouracil (DCF) for Locally Advanced Esophageal and Gastric Adenocarcinoma: Safety and Response Results from a Multi-Center Phase II Trial. *Annals of Oncology*. 2012 Jun; 23(6):1512-7. doi: 10.1093/annonc/mdr465. Epub 2011 Oct 29.
5. Mackay H, Au H, McWhirter E, **Alcindor T**, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM. A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium. *Investigational New Drugs*. 2012 Jun; 30(3):1158-63. doi: 10.1007/s10637-011-9650-4. Epub 2011 Mar 12.

Armen Aprikian

1. Yafi F, Aprikian AG, Fradet Y, Chin J, Izawa J, Rendon R, Estey E, Fairy A, Cagiannos I, Lacombe L, Latouf JB, Bell D, Saad F, Drachenburg D, Kassouf W. Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. **British Journal of Urology International, 10:1317, 2012**
2. Violette P, Abourbih S, Szmanski C, Tanguay S, Aprikian AG, Matthews K, Brimo F, Kassouf W. Solitary solid renal mass: Can we predict malignancy? **British Journal of Urology International, 10:1464, 2012**
3. Sandhu GS, Aprikian AG, Chin J, Fradet Y, Izawa J, Estey J, Fairy A, Rendon R, Cagiannos E., Lacombe L, Latouf JB, Bell D, Kassouf W, Drachenburg D. Outcomes of P0N0 at radical cystectomy: The Canadian Bladder Cancer Network Experience. **Canadian Urology Association Journal, 6:116-120, 2012**
4. Brimo F, Wu C, Zeizafoun N, Tanguay S, Aprikian AG, Mansure JJ, Kassouf W. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, muscularis mucosae invasion. **Human Pathology, 44:95-102, 2013**
5. Choucair K, Edjelman J, Brimo F, Aprikian AG, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. *BMC Cancer*, 12:543, 2012
6. Kotb AE, Kovac E, Kassouf W, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannaos I, Lacombe L, Lattouf JB, Bell D, Drachenburg D, Aprikian AG. Radical cystectomy for clinically muscle-invasive bladder cancer: Does prior non-invasive disease affect outcome? *World Journal of Urology* Feb 1, 2012
7. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian AG, Efthasiou F, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castrate-resistant prostate cancer **PLoS One 7:e31259, 2012**

Sarit Assouline

1. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, Ben-Yehuda D, Stock W, Coutre S, Douer D, Heffner LT, Larson M, Seiter K, Smith S, **Assouline S**, Kuriakose P, Maness L, Nagler A, Rowe J, Schaich M, Shpilberg O, Yee K, Schmieder G, Silverman JA, Thomas D, Deitcher SR, Kantarjian H. High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. *J Clin Oncol*. **2012** Nov 19. [Epub ahead of print]
2. Macdonald DA, Assouline SE, Brandwein J, Kamel-Reid S, Eisenhauer EA, Couban S, Caplan S, Foo A, Walsh W, Leber B. [A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186](#). *Leuk Lymphoma*. **2012** Nov 15. [Epub ahead of print]
3. Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, Frances-Lasserre S, Carlile DJ, Crump M. [A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies](#). *Blood*. **2012** May 31;119(22):5118-25. doi: 10.1182/blood-2012-02-408773. Epub **2012** Mar 20.
4. **Sarit Assouline**, [Eftihia Cocolakis](#) and [Katherine L. B. Borden](#) *Review: The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)* *Cancers* 2012, 4(4), 1161-1179; doi:[10.3390/cancers4041161](#)

Laurent Azoulay

1. **Azoulay L**, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of Angiotensin receptor blockers and the risk of cancer. *PLoS One* 2012; 7(12):e50893.
2. Suissa S, **Azoulay L**. Metformin and the risk of cancer: time-related biases in observational studies. *Diabetes Care* 2012; 35(12):2665-73.
3. Abenhaim HA, **Azoulay L**, Holcroft CA, Bure LA, Assayag J, Benjamin A. Incidence, risk factors, and obstetrical outcomes of women with breast cancer in pregnancy. *Breast J* 2012; 18(6):564-8.
4. Le Ray I, Dell'Aniello S, Bonnetain F, **Azoulay L**, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. *Breast Cancer Res Treat* 2012; 135(2):603-9.
5. **Azoulay L**, Dell'Aniello S, Simon TA, Langleben D, Renoux C, Suissa S. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. *BMC Cardiovasc Disord* 2012; 12:49.
6. **Azoulay L**, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. *BMJ* 2012; 344:e3645.
7. Niazi TM, Vuong T, **Azoulay L**, Marijnen C, Bujko K, Nasr E, Lambert C, Duclos M, Faria S, David M, Cummings B. Silver clear nylon dressing is effective in preventing radiation-induced dermatitis in patients with lower gastrointestinal cancer: results from a phase III study. *Int J Radiat Oncol Biol Phys* 2012; 84(3):e305-10.
8. Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, **Azoulay L**, Assayag J, Turcotte R, Hickeson M. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. *AJR Am J Roentgenol* 2012; 198(6):1409-16.

Published peer-reviewed letters

1. **Azoulay L**, Suissa S. Immortal Person-Time Bias in Relation to the Use of Nonsteroidal Anti-inflammatory Drugs and Statins in the Prevention of Esophageal Cancer in Patients with Barrett's Esophagus. *Gastroenterology* 2012; 142(5):e20-1

Nicole Beauchemin

1. A. Arabzadeh*, C. Chan*, A.L. Novvion*, S. Benlolo*, L. DeMarte*, C. Turbide*, P. Brodt, L. Ferri and N. Beauchemin. Host-Related Carcinoembryonic Antigen Cell Adhesion Molecule 1 Promotes Metastasis of Colorectal Cancer. *Oncogene* doi: 10.1038/onc.2012.112. (2012).
2. E. Xu*, A. Charbonneau, Y. Rolland, K. Bellmann, K. Siminovitch, B.G. Neel, N. Beauchemin and A. Marette. Hepatocyte-specific SHP-1 disruption uncouples liver insulin resistance from hepatic steatosis and inflammation in diet-induced obesity. *Diabetes* 61(8):1949-58 (2012).
3. L. Chen, Z. Chen, K. Baker, E. M. Halvorsen, M. B. Flak, G. Gerber, Y.-H. Huang, J. C. Arthur, K. J. Dery, T. Nagaishi, N. Beauchemin, K. V. Holmes, J. E. Shively, C. Jobin, A. B. Onderdonk, L. Bry, D. E. Higgins, R. S. Blumberg. The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction. *Immunity*: 37(5):930-46 (2012).
4. A. Arabzadeh and N. Beauchemin. Stromal CEACAM1 expression regulates colorectal cancer metastasis. *OncoImmunol.* 1(7):1205-1207 (2012).

Franck Bladou

1. Haddad RL, Patel MI, Vladica P, Kassouf W, **Bladou F**, Anidjar M. Percutaneous Radiofrequency Ablation of Small Renal Tumors Using CT-Guidance: A Review and Its Current role. *Urol J.* 2012 Fall;9(4):629-38
2. Walz J, **Bladou F**, Rousseau B, Laroche J, Salem N, Gravis G, Briganti A, Chun FK, Karakiewicz PI, Fournier G. Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. *Urology.* 2012 Mar;79(3):546-51.
3. Moureau-Zabotto L, Chetaille B, **Bladou F**, Dauvergne PY, Marcy M, Perrot D, Guiramand J, Sarran A, Bertucci F. Solitary fibrous tumor of the prostate: case report and review of the literature. *Case Rep Oncol.* 2012 Jan;5(1):22-9.
4. Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, Hermieu JF, Amarenco G, Karsenty G, Saussine C, Barbot F; VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. *Eur Urol.* 2012 Mar;61(3):520-9.
5. Minaya P, Baumstarck K, Berbis J, Goncalves A, Barlesi F, Michel G, Salas S, Chinot O, Grob JJ, Seitz JF, **Bladou F**, Clement A, Mancini J, Simeoni MC, Auquier P. The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer. *Eur J Cancer.* 2012 Apr;48(6):904-11.
6. Bastide C, Rossi D, Lechevallier E, **Bladou F**, Barriol D, Bretheau D, Grisoni V, Mancini J, Giusiano S, Eghazarian C, Van Hove A. Seminal vesicle invasion: what is the best adjuvant treatment after radical prostatectomy? *BJU Int.* 2012 Feb;109(4):525-30; discussion 531-2.

7. Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P, **Bladou F**, Gravis G. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? *Ann Oncol*. 2012 Mar;23(3):714-21.

Nathaniel Bouganim

1. Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M. Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. *Curr Oncol*. 2012 Dec;19(6):e414-21. doi: 10.3747/co.19.1074.
2. Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Dent S, Mirsky D, Chasen M, Caudrelier JM, Clemons M. Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma. *Curr Oncol*. 2012 Aug;19(4):e270-9. doi: 10.3747/co.19.974.
3. Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ. Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience. *Curr Oncol*. 2012 Aug;19(4):e239-43. doi: 10.3747/co.19.948.
4. Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M. Prospective Validation of a Prediction Tool for Identifying Patients at High Risk for Chemotherapy-Induced Nausea and Vomiting. *J Support Oncol*. 2012 Jul 2. [Epub ahead of print]
5. Fralick M, Hilton JF, Bouganim N, Clemons M, Amir E. Dual blockade of HER2 - twice as good or twice as toxic? *Clin Oncol (R Coll Radiol)*. 2012 Nov;24(9):593-603. doi: 10.1016/j.clon.2012.05.009. Epub 2012 Jun 28.
6. I. Kuchuk , MD, A. Paterson , MD, E. Amir , MB PhD M. Clemons , MB BS MD N. Bouganim, MD Meeting Report Treatment recommendations for the use of bone-targeted agents in 2011—report from the 6th Annual Bone and the Oncologist New Updates meeting. *Current Oncology*, Vol 19, No 5 (2012)

Robin Cohen

1. *Henry M, *Trickey B, *Nuoxin Huang L, Cohen SR. How is cancer recently portrayed in Canadian newspapers compared to 20 years ago? *Support Care Cancer*. 2012; 20:49-55. DOI: [10.1007/s00520-010-1049-9](https://doi.org/10.1007/s00520-010-1049-9)
2. Crooks VA, Williams A, Stajduhar KI, Cohen SR, Allan D, Brazil K. Family caregivers' ideal expectations of Canada's Compassionate Care Benefit. *Health Soc Care Community*. 2012 May; 20(2):172-180. DOI: [10.1111/j.1365-2524.2011.01028.x](https://doi.org/10.1111/j.1365-2524.2011.01028.x)
3. Funk L, Stajduhar KI, Cohen SR, Heyland DK, Williams A. Legitimising and rationalizing in talk about satisfaction with formal health care among bereaved family members. *Sociol Health Illn*. 2012 Sep; 34(7):1010-1024. DOI: [10.1111/j.1467-9566.2011.01457.x](https://doi.org/10.1111/j.1467-9566.2011.01457.x)
4. *Macdonald ME, Liben S, Carnevale F, Cohen SR. An Office or a Bedroom? Challenges for Family-Centered Care in the Pediatric Intensive Care Unit. *J Child Health Care*. 2012 Feb; 16(3):237-249. DOI: [10.1177/1367493511430678](https://doi.org/10.1177/1367493511430678)
5. Kogan NR, Dumas M, Cohen SR. The extra burdens patients in denial impose on their family caregivers. *J Palliat Supp Care*. 2012; 11(2):1-9. Advance online publication. DOI: [10.1017/S1478951512000491](https://doi.org/10.1017/S1478951512000491)

Denis Cornoyer

1. Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenerly A, Lopez I, Kahn A, Murday A, Luminari S, **Cornoyer D**, Locatelli F, Ray P, Mattison DR. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). *J Gen Intern Med.* 2012 Dec;27(12):1697-703.

François DeBlois

1. S. Devic, N. Tomic, S. Aldelajan, F. DeBlois, Jan Seuntjens, M. F. Chan, D. Lewis, "Linearization of dose-response curve of the radiochromic film dosimetry system", *Med. Phys.* 39 (8), 4850- (2012).
2. M. Heravi, N. Tomic, L. Liang, S. Devic, J. Holmes, F. DeBlois, D. Radzioch, T. Muanza, Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model, *Anticancer Drugs.* 2012 Jun;23(5):525-33.

Pnina Brodt

1. *Li S., Wang N. and Brodt P. Metastatic cells can escape the pro-apoptotic effects of an inflammatory microenvironment by utilizing TNF-alpha to increase IL-6 production and signalling- *Cancer Research*, 72: 865-875, 2012
2. Arabzadeh A., Chan C., Nouvion A-L., Breton V., S Benlolo S., L de Marte, C Turbide, Brodt P., Ferri L., and Beauchemin N. Host-related Carcinoembryonic Antigen Cell Adhesion Molecule 1 Promotes Metastasis of Colorectal Cancer. *Oncogene*, April 2012, Epub ahead of print
3. Eefsen-Løvendahl R. Van den Eynden G.G. Høyer-Hansen G., Brodt P., Laerum O.D., Vermeulen P.B., Christensen J., Wettergren A., Federspiel B., Willemoe G.L., Vainer B., Østerlind K. and Illemann M. Histopathological growth pattern, proteolysis and angiogenesis in chemo-naïve patients resected for multiple colorectal liver metastases – *J Oncol.* 2012; 2012: 907971. Published online 2012 August 2
4. Brodt P. Surviving host innate immunity: Cancer cells can turn a deadly assault into an advantage. *OncoImmunology- OncoImmunology*, 1(9): 1601–1603, Dec 2012 - Invited commentary
5. Seccarecia E. and Brodt P. The role of the insulin-like growth factor-I receptor in malignancy: An update. *Growth Hormone and IGF Research*, 22 (6): 193-199, 2012 - Invited review

Issam El Naqa

1. Ellen X. Huang, J. D. Bradley, **I. E. Naqa**, A. Hope, P. Lindsay, W. Bosch, J. Matthews, W. Sause, M. V. Graham, and J. O. Deasy, Modeling the risk of acute esophagitis for Mallinckrodt Institute of Radiology and RTOG 93-11 lung cancer patient cohorts, *IJROBP*, 2012 Apr 1;82(5):1674-9.
2. Hiram Gay, Joseph H. Barthold, Elizabeth O'Meara, Walter R. Bosch, Ph.D.,* **Issam El Naqa**, Rawan Al-Lozi, Seth A. Rosenthal, Colleen Lawton, W. Robert Lee, M.D. Howard Sandler, M.D., Anthony Zietman, Robert Myerson, Laura A. Dawson, Christopher Willett, Lisa A. Kachnic, Anuja Jhingran, Lorraine Portelance, Janice Ryu, William Small, Jr., David Gaffney, Akila N. Viswanathan, and Jeff M. Michalski, "Pelvic Normal Tissue

Contouring Guidelines for Conformal Radiation Therapy; A Radiation Therapy Oncology Group Consensus Panel Atlas,” IJROBP, Jul 1;83(3):e353-62, 2012.

3. **I El Naqa**, “Machine learning methods for predicting tumour response in lung cancer,” WIREs: Datamining and Knowledge Discovery, vol. 2, no. 2, pp 99 – 192, 2012
4. Manushka Vaidya, Kimberly M. Creach, Jennifer Frye, Farrokh Dehdashti, Jeffrey D. Bradley, and **Issam El Naqa**, “Using FDG-PET/CT Image Characteristics for Predicting Radiotherapy Response in Lung Cancer,” Radiotherapy and Oncology, 2012 Feb;102(2):239-4
5. Kimberly M. Creach, **Issam El Naqa**, Jeffrey D. Bradley, Jeffrey R. Olsen, Parag J. Parikh, Robert E. Dryzmala, Charles Bloch, Clifford G. Robinson, “Dosimetric predictors of chest wall pain after lung stereotactic body radiotherapy,” Radiotherapy and Oncology, 2012 Jul;104(1):23-7
6. Habib Zaidi, Carolina Llina Fuentes, and **Issam El Naqa**, “Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma,” Eur J Nucl Med Mol Imaging, 2012 May;39(5):881-91
7. Sangkyu Lee, Gabriela Stroian, Neil Kopek, Mahmood AlBahhar, Jan Seuntjens and **Issam El Naqa**, Analytical modeling of regional radiotherapy dose response of lung, Phys. Med. Biol. 57 3309–3321, 2012.
8. **Issam El Naqa**, Piotr Pater, Jan Seuntjens, Monte Carlo Role in Radiobiological Modeling of Radiotherapy Outcomes, Phys. Med. Biol. 57 R75-R97, 2012.
9. Beth Kidd, **Issam El Naqa**, Robert Drzymala, and Jeffrey Bradley, FDG-PET and Lung Cancer Outcome After Stereotactic Radiation Therapy , Gyn Onc, 2012 Oct;127(1):136-40
10. Matthew E. Johnson, Gisele C. Pereira, **Issam M. El Naqa**, S. Murty Goddu, Rawan Al-Lozi, Aditya Apte, David B. Mansur, “Determination of planning target volume for whole stomach irradiation using daily megavoltage CT images,” Practical Radiation Oncology, in press, 2012

Book chapters

1. **El Naqa I.**, “Level Sets for Radiation Therapy Planning,” Image Processing in Radiotherapy Applications (K. Brock, Editor). Taylor & Francis, in press
2. **El Naqa I.**, Yang, “The Role of Content-Based Image Retrieval in Mammography CAD,” Computational Intelligence in Biomedical Imaging, (K. Suzuki, Editor). Springer-Verlag, in press.
3. **El Naqa I.**, “ Outcome modeling”, Informatics In Radiation Oncology, Editors (Curran & Starkschall), Taylor & Francis, submitted.
4. **El Naqa I.**, Multimodality imaging for tumor volume definition in radiation oncology. Editor: Jinshan Tang, SPIE Publishing, submitted

Michael Evans

1. T. Connell, A. Alexander, M.Evans, J. Seuntjens; **An experimental feasibility study on the use of scattering foil free beams for modulated electron radiotherapy**. Physics in Medicine and Biology 57, 3259 - 3272; 2012.
2. M. Evans, R.Ruo, J. Seuntjens, C.R. Freeman, W. Parker: **RapidArc total body photon irradiation: a feasibility study**: Proceedings of the annual meeting of the Canadian Organization of Medical Physicists (COMP) and the Canadian College of Physicists in Medicine (CCPM), pp 172 - 174, Halifax, NS July 11 - 14 , 2012.
3. M. Serban, R.Ruo, A. Sarfehnia, W. Parker, M. Evans: **Commissioning of the Varian**

ECLIPSE eMLC algorithm for clinical electron treatment planning: Proceedings of the annual meeting of the Canadian Organization of Medical Physicists (COMP) and the Canadian College of Physicists in Medicine (CCPM), pp 214 - 216, Halifax, NS July 11 - 14, 2012.

4. R. Katchadourian, S. Davis, M. Evans, A. Licea, J. Seuntjens, J. Kildea: **Neutron production around a radiation therapy bunker – monte carlo simulations and physical measurements:** Proceedings of the annual meeting of the Canadian Organization of Medical Physicists (COMP) and the Canadian College of Physicists in Medicine (CCPM), pp 400 - 402, Halifax, NS July 11 - 14 , 2012.

Lorenzo Ferri

1. Hanna W, Sudarshan M, Roberge D, David M, Washke K, Mayrand S, Alcondor T, **Ferri L**. What is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer? Current Oncology 2012 April; 19(2):e66-69. Impact Factor = 1.8
2. **Ferri L**, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, Artho G, Thirlwell M. Peri-operative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: A multicenter phase II trial. Annals of Oncology 2012 Jun; 23(6):1512-1517. Impact Factor = 6.4
3. Arabzadeh A, Chan C, Nouvion A, Breton V, Benlolo S, Demarte L, Brodt P, **Ferri L**, Beauchemin N. Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer. Oncogene 2012 Apr 2. doi: 10.1038/onc.2012.112 [Epub ahead of print]. Impact Factor =7.4
4. Sudarshan M, **Ferri L**. A Critical Review of Minimally Invasive Esophagectomy. Accepted for publication Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 2012 Aug; 22(4):310-318. Impact Factor = 1.0
5. Tabariès S, Dupuy F, Dong Z, Monast A, Annis M, Spicer J, **Ferri L**, Omeroglu A, Basik M, Amir E, Clemons M, Siegel PM. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Molecular and Cellular Biology 2012 Aug; 32(15):2979-2991. Impact Factor=6.0
6. Aloraini A, Nahal A, **Ferri L**. Transoral endoscopic resection of esophageal liposarcoma. Accepted for publication in Annals of Thoracic Surgery 2012 Nov; 95(5):e121-2. doi: 10.1016/athoracsur.2012.04.130. Impact Factor = 3.8
7. Spicer J, McDonald B, Giannias B, Kubes P, **Ferri L**. Neutrophils promote liver metastasis via Mac-1 mediated interactions with circulating tumor cells. Cancer Research 2012 Aug. 15; 72(16):3919-3927. doi: 10.1158/0008-5472.CAN-11-2393 [Epub ahead of print July 2, 2012]. Impact Factor = 8.2
8. Li C, **Ferri L**, Mulder D, Ncuti A, Neville A, Lee L, Kaneva P, Watson D, Vassiliou M, Carli F, Feldman L. An Enhanced Recovery Pathway Decreases Duration of Stay After Esophagectomy. Surgery 2012 Oct; 152(4):606-616 [Epub ahead of print Aug. 31]. Impact Factor=3.4
9. Sudarshan M, **Ferri L**. A Critical Review of Minimally Invasive Esophagectomy. Surgical Laparoscopy Endoscopy and Percutaneous Technology 2012 Aug; 22(4):310-318
10. Cools-Lartique J, Chang SY, McKendy K, Mayrand S, Marcus V, Fried, GM, **Ferri LE**. Pattern of Esophageal Eosinophilic Infiltration in Patients with Achalasia and Response to Heller Myotomy and Dor Fundoplication. Diseases of the Esophagus 2012 Aug 14; doi: 10.1111/j. 1442-2050.2012.01385.x [Epub ahead of print]

11. Chan CH, Cools-Lartigue J, Marcus VA, Feldman LS, **Ferri LE**. The Impact of Incidental Gastrointestinal Stromal Tumours on Patients Undergoing Resection of Upper Gastrointestinal Neoplasms. Canadian Journal of Surgery 2012 Dec; 55(6):366-370. doi: 10.1503/cjs.00911 [Epub ahead of print]
12. Alcindor T, **Ferri LE**, Marcus V, Andalib A, Hickeson M, Artho G, Chasen M, Thirlwell MP, Ades S. Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: Correlation between response to treatment and outcome. Medical Oncology 2013 Mar; 30(1):377. doi: 10.1007/s12032-012-0377-7. [Epub 2012 Dec. 29]
13. Picard M, Jung B, Liang F, Azuelos I, Hussain S, Goldberg P, Godin R, Danialou G, Chaturvedi R, Rygiel K, Matecki S, Jaber S, Des Rosiers C, Karpati G, **Ferri L**, Buelle Y, Turnbull DM, Taivassalo T, Petrof BJ. Mitochondrial Dysfunction and Lipid Accumulation in the Human Diaphragm during Mechanical Ventilation. American Journal of Respiratory and Critical Care Medicine 2012 Dec. 1;186(11):1140-1149.

Tanya Fitzpatrick

1. **Fitzpatrick, T. R.**, Edgar, L., & Holcroft, C. (2012). Assessing the Relationship between Physical Fitness Activities, Cognitive Health and Quality of Life among Older Breast Cancer Survivors. *Journal of Psychosocial Oncology*, 30, 556-572.

William Foulkes

1. Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson AM, Ghadirian P, **Foulkes WD**, Tischkowitz M, Narod SA, Provencher D, Tonin PN. The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent. *Breast Cancer Res Treat*. 2012 Jan;131(1):333-40. Erratum in: *Breast Cancer Res Treat*. 2012 Jan;131(1):341.
2. Heravi-Moussavi A, Anglesio MS, Cheng S-WG, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan ANC, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee C-H, Zhao C, Young RH, Aparicio SA, Sorensen PHB, Woo MMM, Boyd N, Jones SJM, Hirst M, Marra MA, Gilks B, Shah SP, **Foulkes WD**, Morin GB, Huntsman DG. Recurrent somatic DICER1 mutations in non-epithelial ovarian cancers. *N Engl J Med*. 2012 Jan 19;366(3):234-42.
3. Natrajan R, Mackay A, Lambros MB, Weigelt B, Wilkerson PM, Manie E, Grigoriadis A, A'hern R, van der Groep P, Kozarewa I, Popova T, Mariani O, Turaljic S, Furney SJ, Marais R, Rodrigues DN, Flora AC, Wai P, Pawar V, McDade S, Carroll J, Stoppa-Lyonnet D, Green AR, Ellis IO, Swanton C, van Diest P, Delattre O, Lord CJ, **Foulkes WD**, Vincent-Salomon A, Ashworth A, Henri Stern M, Reis-Filho JS. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *J Pathol*. 2012 Feb 23.
4. Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, Fitzgerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, Powell I, Bailey-Wilson JE, Cropp CD, Simpson C, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, **Foulkes WD**, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB; International Consortium for Prostate Cancer Genetics. Chromosomes

- 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. *Prostate*. 2012 Mar;72(4):410-23.
5. Kotsopoulos J, Lubinski J, Salmena L, Lynch HT, Kim-Sing C, **Foulkes WD**, Ghadirian P, Neuhausen SL, Demsky R, Tung N, Ainsworth P, Senter L, Eisen A, Eng C, Singer C, Ginsburg O, Blum J, Huzarski T, Poll A, Sun P, Narod SA, Hbcc HB. Breastfeeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. *Breast Cancer Res*. 2012 Mar 9;14(2):R42.
 6. Liu S, Lachapelle J, Leung S, Gao D, **Foulkes WD**, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. *Breast Cancer Res*. 2012 Mar 15;14(2):R48.
 7. **Foulkes W**. Epigenetic modification and cancer: mark or stamp? *Endocr Relat Cancer*. 2012 Apr 10;19(2):C23-7.
 8. Osher DJ, De Leeneer K, Michils G, Hamel N, Tomiak E, Poppe B, Leunen K, Legius E, Shuen A, Smith E, Arseneau J, Tonin P, Matthijs G, Claes K, Tischkowitz MD, **Foulkes WD**. Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. *Br J Cancer*. 2012 Apr 10;106(8):1460-3.
 9. Appleby-Tagoe JH, **Foulkes WD**, Palma L. Reading Between the Lines: A Comparison of Responders and Non-responders to a Family History Questionnaire and Implications for Cancer Genetic Counselling. *J Genet Couns*. 2012 Apr;21(2):273-91.
 10. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallée MP, Tavgigian S, Concannon P, **Foulkes WD**; Leslie Bernstein, The WECARE Study Collaborative Group, Bernstein JL, Begg CB Rare germline mutations in PALB2 and breast cancer risk: A population-based study. *Hum Mutat*. 2012 Apr;33(4):674-80.
 11. Arnes JB, Stefansson IM, Straume O, Baak JP, Lønning PE, **Foulkes WD**, Akslen LA. Vascular proliferation is a prognostic factor in breast cancer. *Breast Cancer Res Treat*. 2012 Jun;133(2):501-10.
 12. McGee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung N, Kim-Sing C, Karlan B, **Foulkes WD**, Ainsworth P, Ghadirian P, Senter L, Eisen A, Sun P, Narod SA. Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers. *Obesity (Silver Spring)*. 2012 Jun;20(6):1288-92.
 13. Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, **Foulkes WD**, Mæhle L, Møller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Stanford JL, Karyadi DM, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Thibodeau SN, McDonnell SK, Hebring S, Lange EM, Cooney KA, Tammela TL, Schleutker J, Maier C, Borchum S, Hoegel J, Grönberg H, Wiklund F, Emanuelsson M, Cancel-Tassin G, Valeri A, Cussenot O, Isaacs WB. Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families. *BMC Med Genet*. 2012 Jun 19;13(1):46.
 14. Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P, Stawicka M, **Foulkes WD**, Kilar E, Kim-Sing C, Neuhausen SL, Armel S, Gilchrist D, Sweet K, Gronwald J, Eisen A, Gorski B, Sun P, Narod SA; The Hereditary Breast Cancer Clinical Study Group. The risk of breast cancer in women with a BRCA1 mutation from north america and poland. *Int J Cancer*. 2012 Jul 1;131(1):229-34.
 15. Jin G, Lu L, Cooney KA, Ray AM, Zuhlke KA, Lange EM, Cannon-Albright LA, Camp NJ, Teerlink CC, Fitzgerald LM, Stanford JL, Wiley KE, Isaacs SD, Walsh PC, **Foulkes WD**,

- Giles GG, Hopper JL, Severi G, Eeles R, Easton D, Kote-Jarai Z, Guy M, Rinckleb A, Maier C, Vogel W, Cancel-Tassin G, Egrot C, Cussenot O, Thibodeau SN, McDonnell SK, Schaid DJ, Wiklund F, Grönberg H, Emanuelsson M, Whittemore AS, Oakley-Girvan I, Hsieh CL, Wahlfors T, Tammela T, Schleutker J, Catalona WJ, Zheng SL, Ostrander EA, Isaacs WB, Xu J; International Consortium for Prostate Cancer Genetics. Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet.* 2012 Jul;131(7):1095-103.
16. Kotsopoulos J, Lubinski J, Lynch HT, Kim-Sing C, Neuhausen S, Demsky R, **Foulkes WD**, Ghadirian P, Tung N, Ainsworth P, Senter L, Karlan B, Eisen A, Eng C, Weitzel J, Gilchrist DM, Blum JL, Zakalik D, Singer C, Fallen T, Ginsburg O, Huzarski T, Sun P, Narod SA. Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. *Cancer Epidemiol Biomarkers Prev.* 2012 Jul;21(7):1089-96.
 17. Sabbaghian N, Hamel N, Srivastava A, Albrecht S, Priest JR, **Foulkes WD**. Germline DICER1 mutation and associated loss of heterozygosity in a pineoblastoma. *J Med Genet.* 2012 Jul;49(7):417-9.
 18. Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, **Foulkes WD**, Blows FM, Bégin LR, Van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. *Br J Cancer.* 2012 Aug 21;107(5):800-7.
 19. Choong CS, Priest JR, **Foulkes WD**. Exploring the endocrine manifestations of DICER1 mutations. *Trends Mol Med.* 2012 Sep;18(9):503-5.
 20. **Foulkes WD**. Size Surprise? Tumour size, nodal status, and outcome after breast cancer. *Curr Oncol.* 2012 Oct;19(5):241-3.
 21. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon-Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, McDonnell SK, Derycke MS, Cancel-Tassin G, Cussenot O, Wiklund F, Grönberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, **Foulkes WD**, Hamel N, Mahle L, Moller P, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB; International Consortium for Prostate Cancer Genetics. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet.* 2012 Oct 12. [Epub ahead of print]
 22. Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirian P, **Foulkes WD**, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Friedman E, Llacuachqui M, Ping S, Narod SA; the Hereditary Breast Cancer Study Group. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. *Br J Cancer.* 2012 Dec 4;107(12):2005-9.
 23. Domchek SM, Tang JB, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, Davidson HR, Nathanson KL, **Foulkes W**, Greenberg RA. Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer. *Cancer Discov.* 2012 Dec 26, [Epub ahead of print]

Eduardo Franco

1. Mahmud SM(\$*), Sangwa-Lugoma G, Nasr SH, Liaras J, Kayembe PK, Tozin RR, Drouin P, Lorincz A, Ferenczy A, **Franco EL**. Comparison of Human Papillomavirus Testing and Cytology for Cervical Cancer Screening in a Primary Health Care Setting in the Democratic Republic of the Congo. Gynecologic Oncology 124: 286-291, 2012.
2. Lapierre SG, Sauthier P, Mayrand MH, Dufresne S, Petignat P, Provencher D, Drouin P, Gauthier P, Dupuis MJ, Michon B, Ouellet S, Hadjeres R, Ferenczy A, **Franco EL**, Coutlée F(*). Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US) with Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. Journal of Clinical Microbiology 50:1240-1244, 2012.
3. Cerigo H, Coutlée F, **Franco EL**, Brassard P(*). Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. Journal of Medical Screening 19: 42-48, 2012.
4. Lau S(\$), Vaknin Z, Ramana-Kumar AV, Halliday D, **Franco EL**, Gotlieb WH(*). Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery. Obstetrics & Gynecology 119: 717-724, 2012.
5. Toporowski A, Harper S, Fuhrer R, Buffler PA, Detels R, Krieger N, **Franco EL**(*). Burden of Disease, Health Indicators, and Challenges for Epidemiology in North America. International Journal of Epidemiology 41: 540-556, 2012.
6. Cerigo H, Macdonald ME, **Franco EL**, Brassard P(*). HPV Detection by Self-Sampling in Nunavik, Quebec: Inuit Women's Sampling Method Preferences. Journal of Aboriginal Health 8: 29-39, 2012.
7. Siegel EM(*), Patel N, Lu B, Lee JH, Nyitray AG, Huang X, Villa LL, **Franco EL**, Giuliano AR. Circulating Biomarkers of Iron Storage and Clearance of Incident Human Papillomavirus Infection. Cancer Epidemiology, Biomarkers and Prevention 21: 859-865, 2012.
8. Siegel E, Patel N, Lu B, Lee JH, Nyitray AG, Craft NE, Frenkel K, Villa LL, **Franco EL**, Giuliano AR(*). Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: Markers of immune response? International Journal of Cancer 131: 219-228, 2012.
9. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam S, Cain J, Garcia FAR, Moriarty A, Waxman A, Wilbur D, Wentzensen N, Downs L, Spitzer M, Moscicki AB, Saraiya M, **Franco EL**, Stoler MH, Schiffman M, Castle PE(*), Myers ER(*). American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. *This article was jointly published in* CA Cancer Journal for Clinicians 62: 147-172, 2012; American Journal of Clinical Pathology 137-516-542, 2012, and Journal of Lower Genital Tract Disease 16: 175-204, 2012.
10. Cerigo H, Macdonald ME, **Franco EL**, Brassard P(*). Inuit Women's Attitudes and Experiences towards Cervical Cancer and Prevention Strategies in Nunavik, Quebec. International Journal of Circumpolar Health 71: 17996, 2012 .
11. Ferguson R(\$), Ramanakumar AV, Koushik A, Coutlée F, Franco EL, Roger M(*), for the Biomarkers of Cervical Cancer Risk (BCCR) Study Team. Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix. International Journal of Cancer 131: E312-E319, 2012.

12. Ribeiro R(§*), Monteiro C, Azevedo A, Cunha V, Ramanakumar AV, Fraga AM, Pina FM, Lopes CMS, Medeiros R, **Franco EL**. Performance of an adipokine pathway-based multilocus genetic risk score for prostate cancer risk prediction. PLoS One 7(6): e39236, 2012.
13. Malagon T, Drolet M, Boily MC, **Franco EL**, Jit M, Brisson J, Brisson M(*). Cross-protective efficacy of two human papillomavirus vaccines : A systematic review and meta-analysis. Lancet Infectious Diseases 12:781-789, 2012.
14. Drolet M, Brisson M(*), Maunsell E, **Franco EL**, Coutlée F, Ferenczy A, Fisher W, Mansi J. The psychosocial impact of an abnormal cervical smear result. Psycho-Oncology 21: 1071-1081, 2012.
15. Landry ME, Salit IE, Rodrigues-Coutlée C, Money D, Rebbapragada A, Tinmouth J, Hankins C, Gorska-Flipot I, Archambault J, **Franco EL**, Coutlée F(*). Ano-genital Infection by Human papillomavirus type 97 in Canadian men and women at risk of or infected with the Human Immunodeficiency Virus. Virology Journal 9: 243, 2012 doi:10.1186/1743-422X-9-243.
16. Van de Velde N, Boily MC, Drolet M, **Franco EL**, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagon T, Brisson M(*). Population-level impact of the bivalent, quadrivalent and nonavalent HPV vaccines: a model-based analysis. Journal of the National Cancer Institute 104: 1712-1723, 2012.
17. **Franco EL**, Sanjose S, Broker TR, Stanley MA, Chevarie-Davis M, Isidean SD, Schiffman M. Human papillomavirus and cancer prevention: Gaps in knowledge and prospects for research, policy, and advocacy. Vaccine 30 (Suppl 5): F175-182, 2012.
18. **Franco EL**. Towards More Eclectic Evidence-based Medicine in Cancer Prevention and Control. Preventive Medicine 55: 552-553, 2012.
19. Ogilvie GS, Krajden M, vanNiekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Stuart GC, **Franco EL**, Coldman AJ. Primary cervical cancer screening with HPV testing compared to liquid based cytology: Results of round 1 of a randomized controlled trial – the HPV FOCAL Study. British Journal of Cancer 107: 1917-1924, 2012.
20. De Pokomandy A(§), **Franco EL**(*). Chapter 15: HPV Infection and Cervical Carcinogenesis: Epidemiology and Prevention. In: Ayhan A, Reed N, Gultekin M, Dursum P (eds.) Textbook of Gynaecological Oncology, 2nd Edition, European Society of Gynecologic Oncology, Gunes Publishing, Ankara, 2012, pp. 73-77, ISBN 978-975-277-387-5.
21. Villa LL, **Franco EL**. Ricardo Renzo Brentani: In Memoriam. Cancer Research 72: 2155-2156, 2012.
22. **Franco EL**, Sullivan KM, Dean AG. Obituary: Andrew Raymond Simons, 1921-2012. American Journal of Epidemiology 176: 174-175, 2012.

Carolyn Freeman

1. **Freeman, C.R.**, Farmer, J-P., Taylor, R.E. Central Nervous System Tumors in Children. In: Principles and Practice of Radiation Oncology. 6th Ed., Chapter 84, 2012.
2. Eldebawy E., Parker W., Abdel Rahman W., **Freeman CR**. Dosimetric study of current treatment options for radiotherapy in retinoblastoma. Int J Radiat Oncol Biol Phys. 2012: 82(3):e501-5

3. Wong P, Lambert C, Agnihotram RV, David M, Duclos M, **Freeman CR**. Ductal carcinoma in situ--the influence of the radiotherapy boost on local control. *Int J Radiat Oncol Biol Phys*. 2012; 82(2):e153-8

Phil Gold

1. Carcinoembryonic Antigen: Past, Present and Future, *Journal of Clinical Chemistry* December 2012

Mark Goldberg

1. Jillian Strauss, Luis Miranda-Moreno, Dan Crouse, Mark S. Goldberg, Nancy Ross, Marianne Hatzopoulou. Investigating the link between cyclist volumes and air pollution along bicycle facilities in a dense urban core. *Transportation Research Part D* 17: 2012; 619-625.
2. Villeneuve PJ, Jerrett M, Su J.G, Burnett R.T., Chen H., Wheeler A.J., **Goldberg M.S.** A cohort study relating urban green space with mortality in Ontario, Canada. *Envir Res* 2012; 115:51-58.
3. Dan L. Crouse, Paul A. Peters, Aaron van Donkelaar, **Mark S. Goldberg**, Paul J. Villeneuve, Orly Brion, Saeeda Khan, Dominic Odwa Atari, Michael Jerrett, C. Arden Pope III, Michael Brauer, Jeffrey R. Brook, Randall V. Martin, David Stieb, Richard T. Burnett. Risk of Non-accidental and Cardiovascular Mortality in Relation to Longterm Exposure to Low Concentrations of Fine Particulate Matter: A Canadian National-level Cohort Study. *Environ Health Perspect* 2012; 120:708-14 (<http://dx.doi.org/10.1289/ehp.1104049>).

Walter Gotlieb

1. Gotlieb WH, Amant F, Advani F, Goswami C, Hirte H, Provencher D, Somani D, Yamada D, Tamby J, Vergote I. Intravenous aflibercept (VEGF Trap) for the treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer : results of a phase II, randomized, double-blind, placebo-controlled study. *Lancet Oncology* 2012 13(2):154-62.
2. Lau S, Vaknin Z, Agnihotram VR, Franco E, Gotlieb R, How J, Halliday D, Gotlieb WH. Outcomes and cost following the introduction of a robotics program for endometrial cancer surgery *Obstet. Gynecol* (2012) 119 (4): 1-10
3. He G, Holcroft CA, Beauchamp MC, Yasmeen A, Ferenczy A, Kendall-Dupont J, Mes-Masson AM, Provencher D, Gotlieb WH. Combination of serum biomarkers to differentiate malignant from benign ovarian tumors. *J Obstet Gynaecol Can* (2012) 34: 567-574
4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminin A, Plante M, Stark D, Qian W, Parmar MK, Oza AM, ICON 7 investigators. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*. (2011) 365(26):2484-96
5. Press JZ, Gotlieb WH. [Controversies in the treatment of early stage endometrial carcinoma](#). *Obstet Gynecol Int*. 2012;2012:578490. Epub 2012 Mar 26
6. Hopkins L, Carrier M, Plante M, Luna V, Gotlieb W, Rambout L. [Surgical venous thromboprophylaxis: a cross-sectional survey of canadian gynaecologic oncologists](#). *J Obstet Gynaecol Can*. 2012 34(7):673-7.

7. How J, Lau S, Press J, Ferenczy A, Pelmus M, Stern J, Probst S, Brin S, Drummond N, Gotlieb W. [Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: A prospective study.](#) *Gynecol Oncol.* (2012) 127 (2): 673-7
8. Crawford B, Piault E, Gotlieb W, Joulain F. [Development and validation of the self-completed ascites impact measure to understand patient motivation for requesting a paracentesis.](#) *Patient Relat Outcome Meas.* 2012 Jul;3:21-30..

Celia Greenwood

1. JS Hamid, **CMT Greenwood**, Joseph Beyene (2012). Weighted kernel Fisher discriminant analysis for Integrating Heterogeneous Data. *Computational Statistics and Data Analysis* 56: 2031-2040.
2. Z Dastani, M-F Hivert, N Timpson, JRB Perry, X Yuan, RA Scott, P Henneman, I M. Heid, JR Kizer, L-P Lyytikainen, C Fuchsberger, T Tanaka, A P Morris, K Small, A Isaacs, M Beekman, S Coassin, K Lohman, L Qi, S Kanoni, J S Pankow, H-W Uh, Y Wu, A Bidulescu, L J Rasmussen-Torvik, **CMT Greenwood**, et al M Ladouceur, J Grimsby, AK Manning, C-T Liu, J Kooner, VE Mooser, P Vollenweider, KA Kapur, J Chambers, NJ Wareham, C Langenberg, R Frants, K Willems-vanDijk, BA Oostra, S M Willems, C Lamina, Thomas Winkler, BM Psaty, RP Tracy, J Brody, I Chen, J Viikari, M Kähönen, PP Pramstaller, M Evans, B St Pourcain, N Sattar, A Wood, S Bandinelli, Olga D. Carlson, JM Egan, S Böhringer, D van Heemst, L Kedenko, K Kristiansson, M-L Nuotio, B-M Loo, T Harris, M Garcia, A Kanaya, M Haun, N Klopp, HE Wichmann, P Deloukas, E Katsareli, DJ Couper, BB Duncan, M Kloppenburg, LS Adair, JB Borja, DIAGRAM+ Consortium, MAGIC Consortium, GLGC Investigators, MuTHER Consortium, JG Wilson, S Musani, X Guo, T Johnson, R Semple, TM Teslovich, MA Allison, S Redline, SG Buxbam, KL Mohlke, I Meulenbelt, CM Ballantyne, GV Dedoussis, FB Hu, Y Liu, B Paulweber, TD Spector, PE Slagboom, L Ferrucci, A Jula, M Perola, O Raitakari, JC Florez, V Salomaa, JG Eriksson, TM Frayling, AA Hicks, T Lehtimäki, GD Smith, DS Siscovick, F Kronenberg, C van Duijn, RJF Loos, DM Waterworth, JB Meigs, J Dupuis, JB Richards (2012). Novel Loci for Adiponectin Levels and their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. *PLoS Genetics* 8(3):e1002607.
3. C Xu, M Ladouceur, JB Richards, A Ciampi, **CMT Greenwood** (2012). Multiple regression methods show great potential for rare variant association tests. *PLoS ONE* 7(8): e41694.
4. HF Zheng, **CMT Greenwood**, JB Richards (2012). Effect of genome-wide genotyping array density on rare variant imputation. *Journal of Genetics and Genomics* 39(10):545-50.
5. Paulina M Wojnarowicz, Kathleen Klein Oros, Michael CJ Quinn, Suzanna L Arcand, Karen Gambaro, Jason Madore, Ashley H Birch, Manon de Ladurantaye, Kurosh Rahimi, Diane M Provencher, Anne-Marie Mes-Masson, **Celia MT Greenwood**, Patricia N Tonin. The Genomic Landscape of *TP53* and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome. *PLoS ONE* 7(9): e45484. doi:10.1371/journal.pone.0045484.
6. P Hu, X Wang, JJ Haitisma, S Furmli, H Masoom, M Liu, AS Slutsky, J Beyene, **C Greenwood**, CD Santos (2012). Microarray meta-analysis identifies acute lung injury biomarkers in donor lungs that predict development of primary graft failure in recipients. *PLoS ONE* 7 (10): e45506. Doi: 10.1371/journal.pone.0045506.
7. Amirreza Haghighi, Melkaye M. Melka, Manon Bernard, Michal Abrahamowicz, Gabriel T. Leonard, Louis Richer, Michel Perron, Suzanne Veillette, Chang Jiang Xu, **Celia M. T.**

Greenwood, Andre Dias⁷, Ahmed El-Sohemy, Daniel Gaudet, Tomas Paus, and Zdenka Pausova*. OPRM1 and fat intake, *Molecular Psychiatry*, [Accepted 19 October 2012].

8. **M Ladouceur**, **CMT Greenwood**, JB Richards, HF Zheng (2012). Empirical Power of Very Rare Variants for Common Traits and Disease: Results from Sanger Sequencing 1,998 Individuals. Submitted to *European Journal of Human Genetics*. [Accepted 22 November 2012].

Book Chapter

1. W Xu, SB Bull, L Mirea, CM Greenwood (2012). Model-free linkage analysis of a binary trait. *Methods in Molecular Biology*: 850: 317-345. *Statistical Human Genetics*. Editors: Robert C. Elston, Jaya Satagopan, Shuying Sun. Humana Press.

Michael Hier

1. Bouhabel S, Payne RJ, Mlynarek A, Hier M, Caglar D, Tamilia M, Are solitary thyroid nodules more likely to be malignant? *Journal of Otolaryngology-Head and Neck Surgery*, 2012 April 1;41(2): 119-23.
2. da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA, Recurrent oral cancer: current and emerging therapeutic approaches. *Front Pharmacol*. 2012;3:149

Tom Hutchinson

1. Irving, J., Park, J., Fitzpatrick, M., Dobkin, P. L., Chen, A., Hutchinson, T. Experiences of Health Care Professionals Enrolled in Mindfulness-Based Medical Practice: A Grounded Theory Model. Springer Science+Business Media, LLC. *Mindfulness* 2012. Published online, September 2012. DOI 10.1007/s12671-012-0147-9.

Nathalie Johnson

1. Singh RR, Ben-Neriah S, **Johnson NA**, Connors JM, Gascoyne RD, Horsman DE. Identification of a novel non-immunoglobulin/MYC translocation t(8;12)(q24;p12) involving the LRMP gene in a primary B-cell lymphoma. A case report. *Leuk Res*. 2012 Jan;36(1):e22-4.
2. Schuetz JM, **Johnson NA***, Morin RD, Scott DW, Tan K, Ben-Nierah S, Boyle M, Slack GW, Marra MA, Connors JM, Brooks-Wilson AR and Gascoyne RD. BCL2 mutations in diffuse large B-cell lymphoma. *Leukemia*. 2012 Jun;26(6):1383-90. * **contributed equally as first authors**
3. Bashashati A,* **Johnson NA***, Khodabakhshi AH, Whiteside MD, Zare H, Scott DW, Lo K, Gottardo R, Brinkman FSL, Connors JM, Slack JW, Gascoyne RD, Weng AP, Brinkman RR. B-cells with high side scatter parameter by flow cytometry correlate with inferior survival in diffuse large B cell lymphoma. *Am J Clin Pathol*. 2012 May;137(5):805-14. * **contributed equally as first authors**
4. **Johnson NA***, Slack JW*, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Horsman DH, Sehn LH, Chan WC, Iqbal J, Meyer P, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Brazier RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Jaffe ES, Staudt LM and Gascoyne RD. Concurrent expression of MYC and BCL2 in R-CHOP treated diffuse large B cell lymphoma. *J Clin Oncol*. 2012 Oct 1;30(28):3452-9. Epub 2012 Jul 30.

Petr Kavan

1. Tap W, **Kavan P** et al: A phase 2 study of ganitumab (AMG 479): a fully human anti-IGF1R antibody, in patients with metastatic Ewing's Family Tumors or Desmoplastic Small Round Cell Tumors, accepted for publication in the Journal of Clinical Oncology, February 2012
2. Mason WP, Belanger K, Nicholas G, Vallières I, Mathieu D, **Kavan P**, Desjardins A, Omuro A, Raymond D: A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. J Neurooncol. 2012 Apr; 107(2):343-9. Epub 2011 Nov 3.
3. Tap W, Demetri G, Barnette P, Desai J, **Kavan P**, Tozer R, Benedetto P, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A: Phase II Study of Ganitumab, a Fully Human Anti-Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients with Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors. JCO May 20, 2012:1849-1856
4. Simoneau E, Aljiffry M, Salman A, Abualhassan N, Cabrera T, Valenti D, El Baage A, Jamal M, **Kavan P**, Al-Abbad S, Chaudhury P, Hassanain M, Metrakos P: Portal Vein Embolization Stimulates Tumor Growth in Patients with Colorectal Cancer Liver Metastases, A retrospective case-control study: HPB Volume 14, Issue 7, pages 461–468, July 2012
5. Jamal M, Hassanain M, Chaudhury P, Tran T, Wong S, Yousef Y, Jozaghi Y, Salman A, Jabbour S, Simoneau E, Al-Abbad S, Al-Jiffry M, Arena G, **Kavan P**, Metrakos P: Staged hepatectomy for bilobar colorectal hepatic metastases. HPB; International Hepato Pancreato Biliary Association, 11/2012; 14(11):782-9.

Neil Kopek

1. Lee S, Stroian G, **Kopek N**, AlBahhar M, Seuntjens J, El Naqa I. Analytical modelling of regional radiotherapy dose response of lung. Phys Med Biol. 2012 Jun 7;57(11):3309-21. doi: 10.1088/0031-9155/57/11/3309. Epub 2012 May 9

Annett Körner

1. **Körner, A.** & Fritzsche, K. (2012). Psychosomatic Services for Melanoma Patients in Tertiary Care. *International Journal of Dermatology*, 51(9), 1060-1067. Doi: 10.1111/j.1365-4632.2011.05228.x.
2. Roberts, N., Czajkowska, Z., Radiotis, G., & **Körner, A.** (2012). Distress and coping strategies among patients with skin cancer. *Journal of Clinical Psychology in Medical Settings*. DOI: 10.1007/s10880-012-9319-y.
3. Meyer, A., Wollbrück, D., Dietz, A., Guntinas-Lichius, O., Meister E.F., Brähler, E., **Körner, A.**, & Singer, S. (2012). [Spouses of Cancer Patients with Laryngectomy – Influences on Psychological Morbidity]. *Psychother Psychosom Med Psychol*, 62, 163-169.
4. Ernst, J., Götze, H., Brähler, E., **Körner, A.**, & Hinz, A. (2012). Quality of life of parents diagnosed with cancer – Change over time and influencing factors. *European Journal of Cancer Care*, 21 535-541. DOI: 10.1111/j.1365-2354.2012.01330.x IF 1.138
5. Thombs BD, Jewett LR, Assassi S, Baron M, Bartlett SJ, Maia AC, El-Baalbaki G, Furst DE, Gottesman K, Haythornthwaite JA, Hudson M, Impens A, **Körner A**, Leite C, Mayes MD, Malcarne VL, Motivala SJ, Mouthon L, Nielson WR, Plante D, Poiraudreau S, Poole JL, Pope J, Sauve M, Steele RJ, Suarez-Almazor ME, Taillefer S, van den Ende CH, Arthurs E, Bassel M, Delisle V, Milette K, Leavens A, Razykov I, Khanna D. (2012). New directions for

patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). *Clinical and Experimental Rheumatology*, 30(2, Suppl 71), S23-29.

Antonis Koromilas

1. Daba A, Koromilas AE, Pantopoulos K 2012 “Alternative ferritin mRNA translation via internal initiation.” *RNA* 18:547-56.
2. Bettaieb A, Matsuo K, Matsuo I, Wang S, Melhem R, Koromilas AE, Haj FG 2012 “Protein tyrosine phosphatase 1B deficiency potentiates PERK/eIF2 α signaling in brown adipocytes.” *PLOS One* 7:e34412
3. Kusio-Kobialka M, Podrzywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, Seferynska I, Stoklosa T, Koromilas AE*, Piwocka K* “The PERK-eIF2 α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.” *Cell Cycle* 11:1-10 *Corresponding authors.

Bernard Lapointe

1. Lapointe, B.J., Sleep Disorders, in Palliative Medicine a Case-based manual, Oxford Medical Publications, Oxford, GB, 2012. P221-228
2. Lapointe, B.J., Dion D. Mouth Care, in Palliative Medicine- a case-based manual, Oxford University Press, 2012. P124-135

Sender Liberman

1. Deckelbaum DL, Ntakiyiruta G, Liberman AS, Razek T, Kyamanywa P, Augmenting Surgical Capacity in Resource-Limited Settings. *The Lancet*, 2012 Aug 25;380(9843):713-4. Epub 2011 Oct 24.
2. Al-Sabah S, Feldman LS, Wongyingsinn M, Charlebois P, Stein B, Kaneva PA, Fried GM, Liberman AS, Single-port Laparoscopic Colorectal Surgery (SPLS): Early Clinical Experience. *Journal of Laparoendoscopic & Advanced Surgical Techniques, Part A* 22 (9), 853-7 (Nov 2012).
3. Kolozsvari NO, Capretti G, Kavena P, Neville A, Carli F, Liberman AS, Charlebois P, Stein B, Vassiliou MC, Fried GM, Feldman LS, Impact of an Enhanced Recovery Program on Short-Term Outcomes after Scheduled Laparoscopic Colon Resection. *Surgical Endoscopy*, 2013 Jan;27(1):133-8.
4. Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, MacFie J, Liberman AS, Soop M, Hill A, Kennedy R, Lobo D, Fearon K, Ljungqvist O, Guideline for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS[®]) Society recommendations. *World Journal of Surgery*, 2013 Feb;37(2):259-84.
5. Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, MacFie J, Liberman AS, Soop M, Hill A, Kennedy R, Lobo D, Fearon K, Ljungqvist O, Guideline for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS[®]) Society recommendations. *Clinical Nutrition*, 2012 Dec;31(6):783-800.
6. Li C, Carli F, Lee L, Charlebois P, Stein B, Liberman AS, Kaneva P, Augustin B, Wongyingsinn M, Gamsa A, Kim DJ, Vassiliou MC, Feldman LS, Impact of Trimodal Prehabilitation Program on Functional Recovery After Colorectal Cancer Surgery: A Pilot Study. *Surgical Endoscopy*, October 2012.

7. Lee L, Mappin-Kasirer B, Lieberman AS, Stein B, Charlebois P, Vassiliou M, Fried GM, Feldman LS, High incidence of symptomatic incisional hernia after midline extraction in laparoscopic colon resection. *Surgical Endoscopy*, November 2012, Volume 26, Issue 11, pp 3180-3185.
8. Al Sabah S, Lieberman AS, Wongyingsinn M, Charlebois P, Stein B, Kaneva PA, Feldman, LS, Fried GM, Single-Port Laparoscopic Colorectal Surgery: Early Clinical Experience. *Journal of Laparoendoscopic & Advanced Surgical Techniques*. November 2012, Vol. 22, No. 9: 853-857
9. Hesselager C, Vuong T, Pahlman L, Richard C, Lieberman AS, Letellier F, Folkesson J, Short Term Outcome after Neoadjuvant High Dose Rate Endorectal Brachytherapy or Short Course External Beam Radiotherapy in Resectable Rectal Cancer. Accepted for publication in *Colorectal Disease* Dec. 2012.

Carmen Loiselle

1. Lee, V. & Loiselle, C. G. (2012). The Salience of Existential Concerns Across the Cancer Control Continuum. *Palliative and Supportive Care*, 10(2), 123-133. doi:10.1017/S1478951511000745
2. Loiselle, C. G., Gelinas, C., Cassoff, J., Boileau, J., & McVey, L. (2012). A pre-post evaluation of the Adler/Sheiner Program (ASP): A nursing informational program to support families and nurses in an intensive care unit (ICU). *Intensive & Critical Care Nursing*, 28(1), 32-40. DOI: 10.1016/j.iccn.2011.11.006
3. Haase, K. & Loiselle, C. G. (2012). Oncology team members' perceptions of a virtual navigation tool for cancer patients. *International Journal of Medical Informatics*, 81, 395-403. DOI: 10.1016/j.ijmedinf.2011.11.001
4. Pelletier, M., Knäuper, B., Loiselle, C., Perreault, R., Mizrahi, C., & Dubé, L. (2012). Moderators of psychological recovery from benign cancer screening results. *Current Oncology*, 19(3), e191-200. doi:10.3747/co.19.935
5. Loiselle, C. G. & Sterling, M. (2012). Views on death and dying among health care workers in an Indian cancer care hospice: Balancing individual and collective needs and perspectives. *Palliative Medicine*, 26(3), 250-256. doi: 10.1177/0269216311400931

Karl Looper

1. Dickinson P, Looper KJ. [Psychogenic nonepileptic seizures: A current overview](#). *Epilepsia*. 2012 Oct;53(10):1679-89. doi: 10.1111/j.1528-1167.2012.03606.x. Epub 2012 Aug 6.
2. Rej S, Abitbol R, Looper K, Segal M. [Chronic renal failure in lithium-using geriatric patients: effects of lithium continuation versus discontinuation-a 60-month retrospective study](#). *Int J Geriatr Psychiatry*. 2012 Jun 4. doi: 10.1002/gps.3841. [Epub ahead of print]
3. Purden M, Mustafa SS, Looper KJ, Zerkowitz P; McGill Early Arthritis Research Group, Baron M. [Caregiving appraisal and disease activity in early inflammatory arthritis](#). *Scand J Caring Sci*. 2012 Jun 7. doi: 10.1111/j.1471-6712.2012.01018.x. [Epub ahead of print]
4. Mustafa SS, Looper KJ, Zerkowitz P, Purden M, Baron M, Early Arthritis Research Group M. Role overload, pain and physical dysfunction in early rheumatoid or undifferentiated inflammatory arthritis in Canada. [Biopsychosoc Med](#). 2012 May 3;6(1):13. [Epub ahead of print]

Mary Ellen Macdonald

1. Stephenson P, Mitchell LM, S Cadell, **ME Macdonald**. Virtual Memorials and the Social Lives of Dead Children. *Health Sociology Review* 2012 21:4:413-431.
2. Affleck W, Glass K, **Macdonald ME**. The Limitations of Language: Male Participants, Stoicism, and the Qualitative Research Interview. 2012 (October; online), *American Journal of Men's Health*.
3. Cerigo H, **Macdonald ME**, Franco EL, Brassard P. HPV Detection by Self-Sampling in Nunavik, Quebec: Inuit women's sampling method preferences. *Journal of Aboriginal Health* 2012 (March): 29-39.
4. Kooiman H, **Macdonald ME**, Carnevale FA, Pineda C, Nottaway W, and Vignola S. Minododazin: Translating an Algonquin tradition of respect into youth well-being in Rapid Lake, Quebec. *Pimatisiwin, A Journal of Indigenous and Aboriginal Community Health* 2012, 10(1):1-15.
5. Nhan C, Laprise R, Douville-Fradet M, **Macdonald ME**, Quach C. Coordination and resource-related difficulties encountered by Quebec's public health specialists and infectious diseases/medical microbiologists in the management of A(H1N1) - A Mixed-Method, Exploratory Survey. *BMC Public Health* 2012,12:115.
6. **Macdonald ME**, Liben S, Carnevale FA, Cohen SR. An Office or Bedroom? A Disconnect between family culture and professional culture in the PICU. *Journal of Child Health Care* 2012 16(3):237-249.
7. Cerigo H, **Macdonald ME**, Franco EL, Brassard P. Inuit women's attitudes and experiences towards cervical cancer and its prevention. *International Journal of Circumpolar Health* 2012, 71: 17996.

Neil MacDonald

Books

1. "Palliative Medicine: a case-based manual" 3rd ed. Oneschuk D, MacDonald N, and Hagen N (editors) Oxford, Oxford University Press: published-March 2012

Koren Mann

1. JJ Schlezinger and **KK Mann**. "Reactive Metabolites and Oxygen Species in Toxicology." In *Principles of Free Radical Biomedicine* H. Schipper and K. Pantopoulos Eds. 2012.

Luke McCaffrey

1. **McCaffrey, L.**¹, Montalbano, J., Mihai, C.*, Macara, I.G. (2012) Loss of the Par3 Polarity Protein Promotes Breast Tumorigenesis and Metastasis. *Cancer Cell*.
2. **McCaffrey, L.**, Macara, I.G. (2012) Signaling Pathways in Cell Polarity. *Cold Spring Harb Perspect Biol* 1; 4(6).

Sarkis Meterissian

1. Cools-Lartigue J. and **Meterissian S**. 2012 Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review *World J. of Surgery* 36: 46-54
2. Jamal M.H., Doi S.A., Rousseau M., Edwards M., Rao C., Barendregt J.J., Snell L. and **Meterissian S**. 2012 Systematic review and meta-analysis of the effect of North American working hours restrictions on mortality and morbidity in surgical patients. *British J. of Surgery* 99:336-344

3. Brunet J., Sabiston C. and **Meterissian S.** 2011 Physical activity and breast cancer survivorship: evidence-based recommendations *American Journal of Lifestyle Medicine* 10:1-17
4. Nouh T., Boutros M., Gagnon R., Reid S., Leslie K., Pace D., Pitt D., Walker R., Schiller D., MacLean A., Hameed M., Fata P., Charlin B. and **Meterissian S.H.** 2012 The script concordance test as a measure of clinical reasoning: a national validation study *Am. J. Surg.* 203:530-534
5. Ari-Nareg Meguerditchian, Dale Dauphinee, Nadyne Girard, Tewodros Eguale, Kristen Riedel, André Jacques, **Sarkis Meterissian**, David L. Buckeridge, Michal Abrahamowicz and Robyn Tamblyn Do Physician Communication Skills Influence Screening Mammography Utilization? *BMC Health Services Research* 12:219
6. Parsyan A., Hernandez G. and **Meterissian S.** 2012 Translation initiation in colorectal cancer *Cancer Metastasis and Reviews* 31:387-395

Wilson Miller

1. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, **Miller WH Jr**, Kaempgen E, Algarra SM, Karaszewska B, Mauch C, Sileni VC, Martin AM, Swann S, Haney P, Mirakhur B, Guckert M, Goodman V, Chapman PB. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *The Lancet* 380(9839):358-65, 2012.
2. Lassen U, **Miller WH Jr**, Hotte S, Evans TRJ, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R and Sawyer MB. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. *Cancer Chemotherapy and Pharmacology*. DOI 10.1007/s00280-012-2038-0. [Epub 2012 Nov 30].

Book Chapter

1. Diaz, Z. and **Miller WH Jr**. Cancer Chemotherapy, In: Principles of Free Radical Biomedicine. Volume III, Chapter 7, (Pantopoulos, K. and Schipper, H. M. eds.), Nova Science Publishers, March 2012.

Thierry Muanza

1. Wong P, **Muanza T**, Hijal T, Masse L, Pillay S, Chasen M, Lowensteyn I, Gold M, Grover S. Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study. *Curr Oncol.* 2012 Jun;19(3):e129-35.
2. Heravi M, Tomic N, Liang L, Devic S, Holmes J, Deblois F, Radzioch D, **Muanza T**. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. *Anticancer Drugs.* 2012 Jun;23(5):525-33.
3. Al-Halabi H, Nantel A, Klekner A, Guiot MC, Albrecht S, Hauser P, Garami M, Bognar L, Kavan P, Gerges N, Shirinian M, Roberge D, **Muanza T**, Jabado N. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. *Acta Neuropathol.* 2011 Feb;121(2):229-39.

Alain Nepveu

1. Vadnais, C., S. Davoudi, M. Afshin, R. Harada, R. Dudley, P.-L. Clermont, E. Drobetsky and Alain Nepveu. CUX1 Transcription Factor is Required for Optimal ATM/ATR-Mediated Responses to DNA Damage. **Nucleic Acids Research**, Feb 8, 2012: 1-13. 2012.
2. Hulea, L., and Alain Nepveu. CUX1 Transcription Factors: From Biochemical Activities and Cell-Based Assays to Mouse Models and Human Diseases. **Gene**, 497: 18-26. 2012.
3. Sansregret, L., and Alain Nepveu. La médecine personnalisée grâce aux signatures d'expression génique : l'exemple du cancer du sein. *Médecine Sciences Amérique*, 1(2):31-39. 2012.

Lawrence Panasci

1. Davidson D, Wang Y, Aloyz R and Panasci LC. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. *Invest New Drugs* Oct 2012 [Epub ahead of print].
2. Amrein L, Shawi M, Grenier J, Aloyz R, Panasci LC. The phosphatidylinositol-3 kinase 1 inhibitor BKM 120 induces cell death in B-chronic lymphocytic leukemia cells in-vitro. *Int J Cancer* Dec 2012 [Epub ahead of print].
3. Lovato A, Panasci LC, Witcher M. Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp-inhibitors? *Pharmacol* 3:202, 2012.

Books

1. *Advances in DNA Repair in Cancer Therapy (Cancer Drug Discovery and Development)* by Lawrence Panasci, Raquel Aloyz and Moulay Alaoui-Jamali -Dec 6 2012) 320 pages published by Springer.

Valerie Panet-Raymond

1. Panet-Raymond, V., Ansbacher, W., Zavgorodni, S., Bendorffe, B., Nichol, Al., Truong, PT., Beckham, W., Vlachaki, M. (2012) Coplanar versus noncoplanar intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) treatment planning for fronto-temporal high-grade glioma* *Journal of Applied Clinical Medical Physics*. 13(4):3826.
2. Petrecca K, Guiot MC, Panet-Raymond V, Souhami L. (2012) Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. *J Neurooncol*. 2013 Jan;111(1):19-23. Epub 2012 Oct 10.

Morag Park

1. Pla-Roca M, Leulmi RF, Tourekhanova S, Bergeron S, Laforte V, Moreau E, Gosline SJC., Bertos N, Hallett M, Park M, Juncker D. Antibody Colocalization Microarray: A Scalable Technology for Multiplex Protein Analysis in Complex Samples. **Molecular and Cellular Proteomics**. 2012 Apr;11(4):M111.011460.
2. Wang Y, Roche O, Xu C, Moriyama EH, Heir P, Chung J, Roos F, Chen E, Finak G*, Milosevic M, Wilson BC, Teh B, Park M, Irwin M, and Ohh M. Hypoxia promotes ligand-independent EGFR signalling via HIF-mediated upregulation of caveolin-1. **Proc. Natl. Acad. Sci. USA** 2012 Mar 27;109(13):4892-7. Epub 2012 Mar 12.
3. Lai AZ, Durrant M, Zuo D, Ratcliffe CD, Park M. [Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer.](#) **J Biol Chem**. 2012 Mar 9;287(11):8048-59

4. Fathers K, Bell E, Rajadurai CV, Cory S, Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, Grosset AA, Gaboury L, Hallett M, Siegel P, Park M. Crk adaptor proteins act as key signaling integrators for breast cancer growth and metastasis. **Breast Cancer Research Breast Cancer Res.** 2012 May 8;14(3):R74.
5. Parachoniak CA, Park M. [Dynamics of receptor trafficking in tumorigenicity.](#) **Trends Cell Biol.** 2012 Mar 5. 2012 May;22(5):231-40 PMID:22397948
6. Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuiblé M, Naujokas M, Zuo D, Tremblay ML, Park M. [Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia.](#) *J Cell Sci.* 2012 Feb 24. **J Cell Sci.** 2012 Jun 15;125(Pt 12):2940-53.
7. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresch DA, Park M, Bergers G. VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. **Cancer Cell.** 2012 Jul 10;22(1):21-35.
8. Pepin F., Laferrière J, Bertos NR., Sadekova S., Souleimanova S., Zhao H., Finak G., Meterissian S., Hallett M., Park M. Gene expression profiling of breast cancer microvasculature identifies distinct tumor vascular subtypes. **Breast Cancer Research**, 2012 Aug 20;14(4):R120
9. Emily S. Bell and Park M "Models of Crk adaptor proteins in cancer" **Genes & Cancer**, Epub 2012 Oct 7, doi: 10.1177/1947601912459951

Horacio Patrocinio

1. F. Cury, M. Duclos, A. Aprikian, H. Patrocinio, W. Kassouf, G. Shenouda, S. Faria, M. David, L. Souhami, "Single-Fraction High Dose Rate Brachytherapy and Hypofractionated External Beam Radiation Therapy in the Treatment of Intermediate-Risk Prostate Cancer - Long Term Results", *Int J Radiat Oncol Biol Phys.* **82(4)**, 1417-1423, 2012.

Jerry Pelletier

1. Rodrigo, C.M., Cencic, R., Roche, S.P., Pelletier, J. and Porco Jr., J.A. (2012). Synthesis of Rocaglamide hydrozamates and related compounds as eukaryotic translation inhibitors: Synthetic and biological studies. *J. Med. Chem.* **55**: 558-562.
2. Mills, J.R., Malina, A., and Pelletier, J. (2012). Inhibiting Mitochondrial-Dependent Proteolysis of Mcl-1 Promotes Resistance to DNA Damage. *Cell Cycle.* **11**: 88-98.
3. Nasr, Z., Robert, F., Porco Jr., J.A., Muller, W.J., and Pelletier, J. (2012). eIF4F suppression in breast cancer affects maintenance and progression. *Oncogene.* doi:10.1038/onc.2012.105.
4. Robert, F., Mills, J., Agenor, A., Wang, D., Di Marco, S., Cencic, R., Tremblay, M., Gallouzi, I.E., Hekimi, S., Wing, S.S., and Pelletier, J. (2012). Targeting protein synthesis in a Myc/mTOR-driven model of Anorexia-Cachexia Syndrome Delays Its Onset and Prolongs Survival. *Cancer Res.* **72**: 747-756.
5. Lin, C.-J., Nasr, Z., Premrirut, P.K., Porco, J.A. Jr., Hippo, Y., Lowe, S.W., and Pelletier, J. (2012). Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. *Cell Reports.* 1: 325-333.
6. Sun, Y., Atas, E., Lindqvist, L., Sonenberg, N., Pelletier, J., and Meller, A. (2012). The eukaryotic initiation factor eIF4H facilitates loop-binding, repetitive RNA unwinding by the eIF4A DEAD-box helicase. *NAR.* **40**: 6199-6207.

7. Scuoppo, C., Miething, C., Lindqvist, L., Reyes, J., Ruse, C., Appelman, I., Yoon, S., Krasnitz, A., Teruya-Feldstein, J., Pappin, D., Pelletier J., & Lowe, S.W. (2012). A tumor suppressor network relying on the polyamine-hypusine axis. *Nature*. **487**: 244 – 248.
8. Di Marco, S., Cammas, A., Lian, X., Kovacs, E.N., Mazroui, R., Pelletier, J., and Eddine Gallouzi, I. (2012). The eIF4A inhibitor Pateamine A prevents the onset of cytokine-induced muscle wasting. *Nature Communication*. **3**:896. doi: 10.1038/ncomms1899.
9. Galicia-Vázquez, G., Cencic, R., Robert, F., Agenor, A.Q., and Pelletier, J. (2012). A Cellular Response Linking eIF4AI Activity to eIF4AII Transcription. *RNA*, **18**: 1373-1384.
10. Lee, T and Pelletier, J. (2012). Eukaryotic Initiation Factor 4F: A Vulnerability of Tumor Cells. *Future Medicinal Chemistry*. **4**: 19-31.
11. Nasr, Z., and Pelletier, J. (2012). Tumor Progression and Metastasis: Role of Translational Deregulation. *Anticancer Research*. **32**: 3077-3084.
12. Malina, A., Mills, J., and Pelletier (2012). Emerging Therapeutics Targeting mRNA Translation. In. “Cold Spring Harbor Perspective Biol.” (Matthews, M., Sonenberg, N., and Hershey, J.W.B.). **4**: a012377.
13. Cencic, R., Galicia-Vazquez, G., and Pelletier, J. (2012). Inhibitors of Translation Targeting Eukaryotic Initiation Factor 4A. *In* Methods in Enzymology – RNA Helicases: Analysis of Molecular Mechanisms and Biological Functions (ed. Eckhard Jankowsky). **511**: 437 – 461.

Michael Pollak

1. **Pollak M**. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. *Clini Cancer Res* **18**: 40-50, 2012. Times cited (as of 2012): 3
2. *Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petrucci LA, Birman E, Viollet B, Ferbeyre G, **Pollak MN**. Metformin reduces endogenous reactive oxygen species and associated DNA damage. *Cancer Prev Res (Phila)* **5**: 536-43, 2012.
3. Agurs-Collins T, Rohrmann S, Sutcliffe C, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, **Pollak MN**, Platz EA. Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. *Cancer Causes Control* **23**: 445-54, 2012.
4. Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, **Pollak MN**, Kolonel LN, Le Marchand L. Genetic variants, prediagnostic levels of insulin-like growth factors, insulin and glucose, and the risk of colorectal cancer: The Multiethnic Cohort Study. *Cancer Epidemiol Biomarkers Prev* **21**: 810-20, 2012.
5. **Pollak M**. The insulin and insulin-like growth factor receptor family in neoplasia: an update. *Nat Rev Cancer* **12**: 159-69, 2012.
6. Faupel-Badger JM, Wang Y, Staff AC, Karumanchi SA, Stanczyk FZ, **Pollak M**, Hoover RN, Troisi R. Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. *Cancer Causes Control* **23**: 779-84, 2012.
7. Zhang X, Giovannucci EL, Wu K, Smith-Warner SA, Fuchs CS, **Pollak M**, Willett WC, Ma J. Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. *Br J Cancer* **106**: 1335-41, 2012.

8. Rice MS, Tamimi RM, Connolly JL, Collins LC, Shen D, **Pollak MN**, Rosner B, Hankinson SE, Tworoger SS. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II. *Breast Cancer Res* 14: R44, 2012.
9. **Pollak M**, Gonzalez-Angulo AM. Metformin and hepatic carcinogenesis. *Cancer Prev Res (Phila)* 5: 500-2, 2012.
10. **Pollak M**. Metformin and pancreatic cancer: a clue requiring investigation. *Clin Cancer Res* 18: 2723-5, 2012.
11. Kaplan RC, Buzkova P, Cappola AR, Strickler HD, McGinn AP, Mercer LD, Arnold AM, **Pollak MN**, Newman AB. Decline in circulating insulin-like growth factors and mortality in older adults: Cardiovascular Health Study All-Stars Study. *J Clin Endocrinol Metab* 97: 1970-6, 2012.
12. Rajpathak SN, HE M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, Gunter MJ, **Pollak M**, Kim M, Pessin JE, Beasley J, Wylie-Rosett J, Hu FB, Strickler HD. Insulin-like growth factor axis and risk of type 2 diabetes in women. *Diabetes* 61: 2248-54, 2012.
13. Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker AV, **Pollak MN**. A phase 2 pharmacodynamic study of pre-operative figitumumab in patients with localized prostate cancer. *Clin Cancer Res* 18: 3407-13, 2012.
14. Gunter JH, Lubik AA, McKenzie I, **Pollak M**, Nelson CC. The interactions between insulin and androgens in progression to castrate-resistant prostate cancer. *Adv Urol* 2012: 248607, 2012.
15. Fung TT, Hu FB, Schulze M, **Pollak M**, Wu T, Fuchs CS, Giovannucci E. A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. *Cancer Causes Control* 23: 959-65, 2012.
16. Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, **Pollak M**, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. *Prostate Cancer Prostatic Dis* 15: 346-52, 2012.
17. Jenkins CR, Schevchuk OO, Giambra V, Lam SH, Carboni JM, Gottardis MM, Holzenberger M, **Pollak M**, Humphries RK, Weng AP. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. *Exp Hematol* 40: 715-723, 2012.
18. Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, **Pollak M**, Sonenberg N. Distinct perturbation of the transcriptome by the antidiabetic drug metformin. *Proc Natl Acad Sci USA* 109: 8977-82, 2012.
19. Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JR, Nagendran J, Flores CT, Betof AS, Nelson ER, **Pollak M**, Dash RC, Young ME, Freedland SJ. Exercise modulation of the host – tumor interaction in an orthotopic model of murine prostate cancer. *J Appl Physiol* 113: 263-72, 2012.
20. *Azoulay L, Yin H, Fillion KB, Assayag J, Majdan A, **Pollak MN**, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. *BMJ* 344: e3645, 2012.
21. *Hvid H, Fendt SM, Blouin MJ, Birman E, Voisin G, Svendsen AM, Frank R, Vander Heiden MG, Stephanopoulos G, Hansen BF, **Pollak MN**. Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. *Endocr Relat Cancer* 19: 557-74, 2012.

22. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. *Diabetologia* 55: 1619-32, 2012.
23. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. *Diabetologia* 55: 1607-18, 2012.
24. Gao Y, Katki H, Graubard B, **Pollak M**, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2, and IGFBP3 and risk of advanced colorectal adenoma. *Int J Cancer* 131: E105-13, 2012.
25. Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, **Pollak M**, Morin GB, Sorensen PH. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. *Oncogene* 31: 1334-40, 2012.
26. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, **Pollak M**, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor in breast cancer subtypes. *Breast Cancer Res Treat* 132: 131-42, 2012.
27. Runchey SS, **Pollak MN**, Valsta LM, Coronado GD, Schwarz Y, Breymeyer KL, Wang C, Wang CY, Lampe JW, Neuhouser ML. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study. *Eur J Clin Nutr* 66: 1146-52, 2012.
28. **Pollak M**. Investigating metformin for cancer prevention and treatment: the end of the beginning. *Cancer Discov* 2: 778-90, 2012.
29. Hofmann JN, Liao LM, **Pollak MN**, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue MP. A prospective study of circulating adipokine levels and risk of multiple myeloma. *Blood* 120: 4418-20, 2012.
30. *Javeshghani S, Zakikhani M, Austin S, Bazile M, Blouin MJ, Topisirovic I, St-Pierre J, **Pollak MN**. Carbon source and myc expression influence the antiproliferative actions of metformin. *Cancer Res* 72: 6257-67, 2012.
31. Rice MS, Tworoger SS, Rosner BA, **Pollak MN**, Hankinson SE, Tamimi RM. Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies. *Breast Cancer Res Treat* 136: 805-12, 2012.
32. Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, **Pollak M**, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA. Pre-diagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. *Blood* 120: 4929-37, 2012.
33. Eichholzer M, Platz EA, Bienstock JL, Monsegue D, Akereyeni F, Hollis BW, Horst R, Rifai N, **Pollak MN**, Barbir A, Agurs-Collins T, Rohrmann S. Racial variation in vitamin D cord blood concentration in white and black male neonates. *Cancer Causes Control* 24: 91-8, 2012.
34. Zakikhani M, Bazile M, Hashemi S, Javeshghani S, Avizonis D, St Pierre J, Pollak MN. Alterations in Cellular Energy Metabolism Associated with the Antiproliferative Effects of the ATM Inhibitor KU-55933 and with Metformin. *PLoS One* 7: e49513, 2012.

35. Song Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, **Pollak M**, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. *J Nutr.* 2012 Dec 19. *Epub ahead of print.*
36. Evdokimova V, Tognon CE, Benatar T, Yang W, Krutikov K, **Pollak M**, Sorensen PH, Seth A. IGF1BP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. *Sci Signal* 5: ra92, 2012.
37. Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, Rifai N, **Pollak MN**, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. *J Natl Cancer Inst.* 2012 Dec 14. *Epub ahead of print.*
38. Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, Lacroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, **Pollak MN**, Veenstra TD, Xu X, Lacey JV. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. *Endocr Relat Cancer.* 2012 Dec 5. *Epub ahead of print.*
39. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, **Pollak MN**. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. *Br J Cancer* 107: 2024, 2012.

Joshua Press

1. **Press JZ**, Reyes M, Pitteri SJ, Pennil Christopher, Garcia R, Boff BA, Hanash SM, Swisher EM. Microparticles from Ovarian Carcinomas are Shed into Ascites and Promote Cell Migration. *Int J Gynecol Cancer* 2012;22:546-52.
2. **Press JZ** and Gotlieb W. Controversies in the treatment of early stage endometrial carcinoma. *Obstet Gynecol Int* 2012;578490.
3. Smith NL, Welsch P, **Press JZ**, Agnew A, Garcia R, Swisher EM. E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium. *Genes Chromosomes Cancer.* 2012;51:1054-62.
4. How JA, Lau S, **Press JZ**, Ferenczy A, Pelmus M, Stern J, Probst S, Brin S, Drummond NS, Gotlieb WH. Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: a prospective study. *Gynecol Oncol* 2012 Nov;127(2):332-7.

Agnihotram Ramana-Kumar

1. Ribeiro R, Monteiro C, Pina F, Ramanakumar AV, Azevedo A, Cunha V, Lopes C, Medeiros R, Franco EL. Body adiposity, adipokine pathways-based genetic risk score and prostate cancer risk. **PLoS One.** 2012;7(6):e39236.
2. Lau S, Vaknin Z, Ramana-kumar AV, Halliday D, Franco EL, Gotlieb WH. Peri-operative Outcomes and cost comparisons after introducing a robotics program for endometrial cancer surgery. Obstet. Gynecol. 2012 Apr; 119(4):717-24.
3. Gilbert L, Basso O, Sampalis O, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Artho G, Krishnamurthy S, for the DOvE Study Group.. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project **Lancet Oncology.** 2012 Mar;13(3):285-91.
4. Ferguson R, Ramanakumar AV, Koushik A, Coullée F, Roger M, Franco EL. Human leukocyte antigen G polymorphism is associated with an increase risk of invasive cancer of uterine cervix. **International Journal of Cancer.** 2012 Aug 1;131(3):E312-9.

5. Wong P, Lambert C, Agnihotram RV, David M, Duclos M, Freeman CR. International **Journal of Radiation Oncology Biology Physics**. 2012 Feb 1;82(2):e153-8.
6. Ramanakumar AV. Assessment of cervical cancer prevention and treatment strategies in low-resource countries: challenges and revelations. Poverty in India (editor: Chatarjee A). Page 70-74

Siham Sabri

1. Manik Chahal, Bassam Abdulkarim, Yaoxian Xu, Marie-Christine Guiot, Jacob C. Easaw, Nicolas Stifani and Siham Sabri. O⁶-Methylguanine-DNA Methyltransferase is a Novel Negative Effector of Invasion in Glioblastoma Multiforme. *Molecular Cancer Therapeutics*, Nov;11 (11):2440-50. Epub 2012 Sep 17.

Jan Seuntjens

1. C. Gao, **Seuntjens JP**, G.N.Kaufman, N. Tran-Khan, A. Butler, A. Li, H. Wang, M.D. Buschmann, E.J. Harvey and J.E. Henderson (2012) *Mesenchymal Stem Cell Transplantation to Promote Bone Healing*, J. Orthop. Res. **30**(8), 1183-1189. doi: 10.1002/jor.22028. [Online published: January 2012].
2. E. Chung†, E. Soisson and **Seuntjens JP** (2012) *Dose homogeneity specification for reference dosimetry of nonstandard fields*, Med. Phys. **39**(1), 407-414.
3. H. Bouchard, **Seuntjens JP**, H. Palmans (2012) *On charged particle equilibrium violation in external photon fields*, Med. Phys. **39**(3), 1473-1480; <http://dx.doi.org/10.1118/1.3684952> .
4. **Seuntjens JP.**, Beaulieu, L., El Naqa, I., and Despres P., (2012) *Editorial: Special section: Selected papers from the Fourth International Workshop on Recent Advances in Monte Carlo Techniques for Radiation Therapy*, Phys. Med. Biol **57**(11), 4 pages.
5. El Naqa, I., Pater P., **Seuntjens JP**. (2012) *Monte Carlo role in radiobiological modeling of radiotherapy outcomes*, Phys. Med. Biol **57**(11), 3259-72.
6. Connell, T. †, Alexander, A., Evans, M., and **Seuntjens JP** (2012) *An experimental feasibility study on the use of scattering foil free beams for modulated electron radiotherapy*, Phys. Med. Biol **57**(11), 3259-3272.
7. Lee, S. †, Stroian, G., Kopek, N., AlBahhar, M., **Seuntjens JP.**, and El Naqa, I. (2012) *Analytical modelling of regional radiotherapy dose response of lung*, Phys. Med. Biol **57**(11), 3309-3321.
8. Devic S, Tomic N, Aldelaijan S, Deblois F, **Seuntjens JP**, Chan M, Lewis D (2012) *Linearization of dose–response curve of the radiochromic film dosimetry system* Med. Phys. **39**(8), 4850-4857.
9. Alexander A, Soisson E, Renaud MA, **Seuntjens JP** (2012) *Direct aperture optimization for FLEC-based MERT and its application in mixed beam radiotherapy*, Med. Phys. **39**(8), 4820-4831.
10. E. Conneely, A. Alexander, G. Stroian, **Seuntjens JP** (2013) *An investigation into the use of MMCTP to tune accelerator source parameters and testing its clinical application*, JACMP, in press.

Book Chapters

1. Bjerke, H., DeWerd, L., **Seuntjens, J.**, and Bidmead, M. (2012) *Source Calibration*, In “Comprehensive Brachytherapy, Physical and Clinical Aspects”, Section II, Chapter 5, Taylor & Francis, pp. 61-74.

2. Bouchard H and **Seuntjens J** (2012) *Applications of Monte Carlo to radiation dosimetry*, In: Monte Carlo Techniques in Radiathion Therapy (J.Seco and F. Verhaegen, ed), Chapter 4, Taylor & Francis Books, Inc, pp. 43 – 64.

Gayle Shinder

Shinder GA, Paradis, PE, Posman M, Mishagina N, Guay M-P, Linardos D, Batist G. *Patient and Work Flow and Costs Associated with Staff Time and Facility Usage at a Comprehensive Cancer Centre in Quebec, Canada – A Time and Motion Study*. BMC Health Services Research 2012, 12:370 doi:10.1186/1472-6963-12-370. Paper accepted October 22, 2012 and published online October 29, 2012.

Peter Siegal

1. J.J. Northey, Z. Dong, E. Ngan, A. Kaplan, W. R. Hardy, T. Pawson and **P.M. Siegel**. (2012). [Distinct phospho-tyrosine dependent functions of ShcA are required for TGFβ-induced breast cancer cell migration, invasion and metastasis](#). **J Biol Chem** (*epub ahead of print*).
2. B. Faubert, G. Boily, S. Izreig, T. Griss, B. Samborska, Z Dong, F. Dupuy, C. Chambers, B.J. Fuerth, B. Viollet, O. Mamer, D. Avizonis, R. DeBerardinis, **P.M. Siegel**, and R.G. Jones. (2012). [AMPK is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo](#). **Cell Metabolism**. (*epub ahead of print*).
3. A.A. Mourskaia, E. Amir , Z. Dong, K. Tiedemann, S. Cory, A. Omeroglu, N. Bertos, V. Ouellet, M. Clemons, G.L. Scheffer, M. Park, M. Hallett, S.V. Komarova, **P.M. Siegel**. (2012). ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. **Breast Cancer Res**. 14(6): R149.
4. X.Y. Liu, N. Gerges, A. Korshunov, N. Sabha, D.A. Khuong-Quang, A.M. Fontebasso, A. Fleming, D. Hadjadj, J. Schwartzentruber, J. Majewski , Z. Dong, P. Siegel, S. Albrecht, S. Croul, D.T. Jones, M. Kool, M. Tonjes, G. Reifenberger, D. Faury, G. Zadeh, S. Pfister and N. Jabado. (2012) [Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations](#). **Acta Neuropathol**. 124(5):615-625.
5. S. Tabariès, F. Dupuy, Z. Dong, A. Monast, M.G. Annis, J. Spicer, L.E. Ferri, A. Omeroglu, M. Basik, E. Amir, M. Clemons and **P.M. Siegel**. (2012) Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. **Mol. Cell. Biol**. 32(15): 2979-91.
6. K.E. Fathers, E. Hanson , C.V. Rajadurai , S. Cory , H. Zhao , A. Mourskaia , D. Zuo , J. Madore , A. Monast , A-M. Mes-Masson , A-A Grosset , L. Gaboury , M. Hallett , **P.M. Siegel** and M. Park. (2012). Crk adaptor proteins act as key signaling integrators for breast cancer growth and metastasis. **Breast Cancer Res**. 14(3): R74.
7. V. Ouellet and **P.M. Siegel** (2012). CCN3 Modulates Bone Turnover and is a Novel Regulator of Skeletal Metastasis. **J Cell Commun Signal**. 6(2): 73-85.
8. J. Schwartzentruber, A. Korshunov, X-Y. Liu, D.T.W. Jones, E. Pfaff, K. Jacob, D. Sturm, A. M Fontebasso, D-A. Khuong Quang, M. Tönjes, V. Hovestadt, S. Albrecht, A. Nantel, C. Konermann, N. Jäger, T. Rausch, M. Ryzhova, J. Korbel, T. Hielscher, P. Hauser, M. Garami, A. Klekner, L. Bognar, M. Ebinger, M.U. Schuhmann, W. Scheurlen, A. Pekrun, M. Frühwald, W. Roggendorf, C. Kramm, M. Dürken, J. Atkinson, P. Lepage, A. Montpetit, M. Zakrzewska, K. Zakrzewski, P.P. Liberski, Z. Dong, **P. Siegel**, A.E. Kulozik, M. Zapatka, A.

Guha, D. Malkin, J. Felsberg, G. Reifemberger, A. von Deimling, K. Ichimura, V. Peter Collins, H. Witt, T. Milde, O. Witt, C. Zhang, P. Castelo-Branco, P. Lichter, D. Faury, U. Tabori, C. Plass, J. Majewski, S.M. Pfister, N. Jabado. (2012) Exome sequencing identifies frequent driver mutations in histone H3.3 and ATRX-DAXX in pediatric glioblastoma. *Nature*. 482(7384):226-231.

Luis Souhami

1. Alfieri J, Portelance L, **Souhami L**, Steinert Y, McLeod P, Gallant F, Artho G. Development and Impact Evaluation of an e-Learning Radiation Oncology Module. *Int J Radiat Oncol Biol Phys* 82:e573-80, 2012
2. Ezer H, Chachamovich JR, Saad F, Aprikian A, **Souhami L**. Psychosocial Adjustment of Men During the conto Year of Prostate Cancer. *Cancer Nurs* 35:141-7, 2012.
3. Cury FL, Duclos M, Aprikian A, Patrocinio H, Kassouf W, Shenouda G, Faria S, David M, **Souhami L**. Single-fraction high dose rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer – Long term results. *Int J Radiat Oncol Biol Phys* 101:486-489, 2012.
4. Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, **Souhami L**, Lukka H. Pre-treatment risk stratification of patients with prostate cancer. A critical review. *Can Urol Assoc J* 6:121-127, 2012.
5. Vakilian S, **Souhami L**, Melancon D, Zeitouni A. Volumetric Measurement of Vestibular Schwannoma Tumour Growth Following Partial Resection: Predictors for Recurrence. *J Neurol Surg* 73:117-120, 2012.
6. Bloemers MC, Portelance L, Ruo R, Parker W, **Souhami L**. A dosimetric evaluation of dose escalation for the radical treatment of locally advanced vulvar cancer with intensity-modulated radiation therapy. *Med Dos* 37:310-313, 2012.
7. Cardoso CCD, Giordani AJ, Wolosker AMB, Segreto HRC, **Souhami L**, Manso PG, Dias RS, Segreto RA. Protracted hypofractionated radiotehrapy for Graves' ophthalmopathy: a pilot study of clinical and radiological response. *Int J Radiat Oncol Biol Phys* 82:1285-1291, 2012.
8. Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, **Souhami L**, Small W Jr, Berk L, Gaffney D. A Phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: Radiation Therapy Oncology Group Trial 0418. *Int J Radiat Oncol Biol Phys* 84:e23-28, 2012.
9. Roberge D, **Souhami L**, Fortin M-A, Pouliot J-F. Chemosensitized radiosurgery for recurrent brain metastases. *J Neurooncol* 110:265-70; 2012.

Gabriela Stroian

1. D Fontanarosa, S van der Meer, E. Bloemen, G Stroian, F Verhaegen. Magnitude of speed of sound aberration corrections for ultrasound image guided radiotherapy for prostate and other anatomical sites, *Med Phys*, 39, 5286-92, 2012.
2. S. Lee, G. Stroian, N. Kopek, M. AlBahhar, J. Seuntjens and I. El Naqa, Analytical modeling of regional radiotherapy dose response of lung, *Phys. Med. Biol.*, Vol. 57, No. 11, 2012.

Simon Tanguay

1. Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, Cagiannos I, Lacombe L,

- Fradet Y, Jacobsen NE. [Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration.](#) BJU Int. 2012 Nov 13
2. Violette P, Abourbih S, Szymanski KM, Tanguay S, Aprikian A, Matthews K, Brimo F, Kassouf W. [Solitary solid renal mass: can we predict malignancy?](#) BJU Int. 2012 May 22.
 3. Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen N, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Fradet Y, Rendon RA. [The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience.](#) Urology 79: 80, 2012.
 4. Jewett M, Finelli A, Kollmannsberger C, Wood L, Legere L, Basiuk J, Canil C, Heng D, Reaume N, Tanguay S, Atkins M, Bjarnason G, Dancey J, Evans M, Fleshner N, Haider M, Kapoor A, Uzzo R, Maskens D, Soulieres D, Yousef G, Basappa N, Bendali N, Black P, Blais N, Cagiannos I, Care M, Chow R, Chung H, Czaykowski P, Derosa D, Durrant K, Ellard S, Farquharson G, Filion-Brulotte C, Gingerich J, Godbout L, Grant R, Hamilton W, Kassouf W, Kurban G, Lane K, Lattouf J, Lau D, Leveridge M, McCarthy J, Moore R, North S, O'brien P, Pituskin E, Racine P, Rendon R, So A, Sridhar S, Stubbs K, Su Z, Taylor L, Udall T, Venner P, Vogel W, Yap S, Yau P, Cooper M, Giroux N, Miron D, Mosher D, Ross K, Willacy J. [Management of kidney cancer: Canadian kidney cancer forum consensus update 2011.](#) Can Urol Ass J., 6: 16, 2012.

Ivan Topisirovic

1. Herdy B, Jaramillo M, Svitkin YV, Rosenfeld AB, Kobayashi M, Walsh D, Alain T, Sean P, Robichaud N, Topisirovic I, Furic L, Dowling RJ, Sylvestre A, Rong L, Colina R, Costa-Mattioli M, Fritz JH, Olivier M, Brown E, Mohr I, and Sonenberg N. (2012) Translational control of the activation of transcription factor NF- κ B and production of type I interferon by phosphorylation of the translation factor eIF4E. Nat Immunol. 2012 Apr 29. doi: 10.1038/ni.2291.
2. Larsson O*, Masahiro M*, Topisirovic I*, Alain T, Blouin MJ, Pollak M, and Sonenberg N. (2012) Distinct perturbation of the translome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A 2012 May 18, 2012, doi:10.1073/pnas.1201689109. (*equally contributing first authors).
3. Morita M, Ler LW, Fabian MR, Siddiqui N, Mullin M, Henderson VC, Alain T, Fonseca BD, Karashchuk G, Bennett CF, Kabuta T, Higashi S, Larsson O, Topisirovic I, Smith RJ, Gingras AC, Sonenberg N. (2012) A novel 4EHP-GIGYF2 translational repressor complex is essential for mammalian development. Mol Cell Biol. 2012 Jul 2. [Epub ahead of print]
4. Javeshghani S, Zakikhani M, Austin S, Bazile M, Blouin MJ, Topisirovic I, St-Pierre J, Pollak MN (2012) Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res; Published OnlineFirst October 4, 2012; doi:10.1158/0008-5472.CAN-12-2907.
5. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, Zammit D, Marcus V, Metrakos P, Voyer LA, Gandin V, Liu Y, Topisirovic I*, Sonenberg N* (2012) eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 2012 Oct 24. [Epub ahead of print] (*co-corresponding author).

6. Roux, P.P., Topisirovic I. (2012) Regulation of mRNA Translation by Signaling Pathways. In "Translational Control in Biology and Medicine", Cold Spring Harb Perspect Biol doi: 10.1101/cshperspect.a012252

Anna Towers

1. Towers A. How to write lymphedema Case reports, *Pathways Lymphedema Magazine*, Winter 2012, p 9-12
2. Towers A. Lymphedema advocacy, *Pathways Lymphedema Magazine*, Spring 2012, p. 10-11

Books and book chapters

1. Towers A. Adapting compression bandaging for the palliative patient, in *Compression Therapy: a position document on compression bandaging*. International Lymphoedema Framework, UK, June 2012, p 57-61
2. Towers A, Hodgson P. Lymphedema Towers A. Lymphedema, Chapter in MacDonald D, ed. *Palliative Care – A Case-Based Manual*, 3rd edition, Oxford University Press, 2012

Golda Tradounsky

1. Tradounsky G. Palliation of gastrointestinal obstruction. Canadian family physician Medecin de famille canadien. 2012;58(6):648-52, e317-21. Epub 2012/08/04.

Michel Tremblay

1. Hardy S, Julien SG, **Tremblay ML**. Impact of oncogenic protein tyrosine phosphatases in cancer. *Agents Med Chem*. 2012 Jan;12(1):4-18.
2. Doody KM, Bussi eres-Marmen S, Li A, Paquet M, Henderson JE, **Tremblay ML**. T cell protein tyrosine phosphatase deficiency results in spontaneous synovitis and subchondral bone resorption in mice. *Arthritis Rheum*. 2012 Mar;64(3):752-61.
3. Berdnikovs S, Pavlov VI, Abdala-Valencia H, McCary CA, Klumpp DJ, **Tremblay ML**, Cook-Mills JM. PTP1B deficiency exacerbates inflammation and accelerates leukocyte trafficking in vivo. *J Immunol*. 2012 Jan 15;188(2):874-84.
4. Robert F, Mills JR, Agenor A, Wang D, DiMarco S, Cencic R, **Tremblay ML**, Gallouzi IE, Hekimi S, Wing SS, Pelletier J. Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. *Cancer Res*. 2012 Feb 1;72(3):747-56.
5. Lessard L, Labb e DP, Deblois G, B egin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Gigu ere V, **Tremblay ML**. PTP1B Is an Androgen Receptor-Regulated Phosphatase That Promotes the Progression of Prostate Cancer. *Cancer Res*. 2012 Mar 15;72(6):1529-1537. Epub 2012 Jan 26.
6. Labb e DP, Hardy S, **Tremblay ML**. Protein tyrosine phosphatases in cancer: friends and foes! *Prog Mol Biol Transl Sci*. 2012;106:253-306.
7. Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuibler M, Naujokas M, Zuo D, **Tremblay ML**, Park M. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. *J Cell Sci*. 2012 Feb 24. [Epub ahead of print]
8. St-Pierre J, **Tremblay ML**. Modulation of leptin resistance by protein tyrosine phosphatases. *Cell Metab*. 2012 Mar 7;15(3):292-7.
9. Brown JM, Xia J, Zhuang B, Cho KS, Rogers CJ, Gama CI, Rawat M, Tully SE, Uetani N, Mason DE, **Tremblay ML**, Peters EC, Habuchi O, Chen DF, Hsieh-Wilson LCA sulfated

- carbohydrate epitope inhibits axon regeneration after injury. *Proc Natl Acad Sci U S A*. 2012 Mar 27. [Epub ahead of print]
10. Vang T, Liu WH, Delacroix L, Wu S, Vasile S, Dahl R, Yang L, Musumeci L, Francis D, Landskron J, Tasken K, **Tremblay ML**, Lie BA, Page R, Mustelin T, Rahmouni S, Rickert RC, Tautz L. LYP inhibits T-cell activation when dissociated from CSK. *Nat Chem Biol*. 2012 Mar 18. [Epub ahead of print]
 11. Kelly A. Pike¹, and **Michel L. Tremblay**¹. Regulating naïve and memory CD8 T cell homeostasis: a role for protein tyrosine phosphatases *FEBS J*. 2012 Mar 28. doi: 10.1111/j.1742-4658.2012.08587.x. [Epub ahead of print]
 12. Elodie Gomez, Magali Vercauteren, Baptiste Kurtz, Antoine Ouvrard-Pascaud, Paul Mulder, Jean-Paul Henry, Marie Besnier, Aurélie Wagee, Rob Hooft Van Huijsduijnen, Michel L Tremblay, Remy Burcelin, Christian Thuillez and Vincent Richard. Reduction of heart failure by pharmacological inhibition or gene deletion of Protein Tyrosine Phosphatase 1B. *Journal of Molecular and Cellular Cardiology* 2012 Mar 15. [Epub ahead of print]
 13. Wiede F., B. Shields, KS Chew, K. Kyparissoudis, C. van Vliet, S. Galic, **ML. Tremblay**. S. Russell, D. Godfrey, T. Tiganis. Strain-dependent differences in bone development, myeloid hyperplasia, morbidity and mortality in Ptpn2-deficient mice. *PLoS One*. 2012;7(5):e36703. Epub 2012 May 8
 14. Horn KE, Xu B, Gobert D, Hamam BN, Thompson KM, Wu CL, Bouchard JF, Uetani N, Racine RJ, **Tremblay ML**, Ruthazer ES, Chapman CA, Kennedy TE (2012) Receptor Protein Tyrosine Phosphatase Sigma Regulates Synapse Structure, Function and Plasticity. *J Neurochem*. *J Neurochem*. 2012 Apr 21. doi: 10.1111/j.1471-4159.2012.07762.x. [Epub ahead of print]
 15. Mori J, Wang YJ, Ellison S, Heising S, Neel BG, **Tremblay ML**, Watson SP, Senis YA. Dominant Role of the Protein-Tyrosine Phosphatase CD148 in Regulating Platelet Activation Relative to Protein-Tyrosine Phosphatase-1B. *Arterioscler Thromb Vasc Biol*. 2012 Oct 11. [Epub ahead of print]
 16. de Chantemèle EJ, Ali MI, Mintz JD, Rainey WE, **Tremblay ML**, Fulton DJ, Stepp DW. Increasing Peripheral Insulin Sensitivity by Protein Tyrosine Phosphatase 1B Deletion Improves Control of Blood Pressure in Obesity. *Hypertension*. 2012 Nov;60(5):1273-9. doi: 10.1161/HYPERTENSIONAHA.112.196295. Epub 2012 Oct 8.
 17. Bourdeau A., S. Trop , KM. Doody , M. Cruz, DJ. Dumont, **ML. Tremblay**. Inhibition of T cell protein tyrosine phosphatase (TC-PTP) enhances IL-18-dependent hematopoietic progenitor expansion. *Stem Cells*. 2012 Nov 8. doi: 10.1002/stem.1276. [Epub ahead of print]

Robert Turcotte

1. Ghert M, Deheshi B, Holt G, Randall RL, Ferguson P, Wunder J, Turcotte R, Werier J, Clarkson P, Damron T, Benevenia J, Anderson M, Gebhardt M, Isler M, Mottard S, Healey J, Evaniew N, Racano A, Sprague S, Swinton M, Bryant D, Thabane L, Guyatt G, Bhandari M; The PARITY Investigators. Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study. *BMJ Open*. 2012 Nov 28;2(6).
2. David Roberge, Siavosh Vakilian, Yazan Z. Alabed, Robert E. Turcotte, Carolyn R. Freeman, and Marc Hickeson. FDG PET/CT in Initial Staging of Adult Soft-Tissue Sarcoma. *Sarcoma Volume 2012 (2012)*,

3. Singh S, Singh M, Mak IWY, Turcotte R, Ghert M (2012) Investigation of FGFR2-IIIC Signaling via FGF-2 Ligand for Advancing GCT Stromal Cell Differentiation. PLoS ONE 7(10): e46769.
4. Desy NM, Bernstein M, Nahal A, Aziz M, Kenan S, Turcotte RE, Kahn LB. Primary perivascular epithelioid cell neoplasm (PEComa) of bone: Report of two cases and review of the literature. Skeletal Radiol. 2012 Jul 3. [Epub ahead of print]
5. Trabulsi NH, Patakfalvi L, Nassif MO, Turcotte RE, Nichols A, Meguerditchian AN. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: Systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol. 2012 Jul 17. [Epub ahead of print]
6. Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, Azoulay L, Assayag J, Turcotte R, Hickeson M. Correlating Metabolic Activity on 18F-FDG PET/CT With Histopathologic Characteristics of Osseous and Soft-Tissue Sarcomas: A Retrospective Review of 136 Patients. AJR Am J Roentgenol. 2012 Jun;198(6):1409-16
7. Amit Garg, Ayoub Nahal, Robert Turcotte, Roger Tabah, Thierry Alcindor. Primitive Neuroectodermal Tumor (PNET) As Somatic-Type Malignancy Arising From An Extragonadal Germ Cell Tumor: Clinical, Pathological And Molecular Features Of A Case. (Accepted Tumori May 2012)
8. Mak IW, Turcotte RE, Ghert M. Transcriptomic & proteomic analyses in bone tumor cells: Deciphering parathyroid hormone-related protein (PTHrP) regulation of the cell cycle and apoptosis. Bone Miner Res. 2012 Apr 16. doi: 10.1002/jbmr.1638. [Epub ahead of print]
9. Moreau LC, Turcotte R, Ferguson P, Wunder J, Clarkson P, Masri B, Isler M, Dion N, Werier J, Ghert M, Dehesi B; the Canadian Orthopaedic Oncology Society (CANOOS). Myxoid Round Cell Liposarcoma (MRCLS) Revisited: An analysis of 418 Primarily Managed Cases. Ann Surg Oncol. Vol 19:4 2012, Page 1081-1088
10. **Turcotte RE**, Fabbri N. L'adamantinome. Encyclopédie Médico-Chirurgicale; Appareil Locomoteur. Dorfmann H ed.. Elsevier. 2012, 14-727
11. Fabbri N, **Turcotte RE**. La dysplasie ostéofibreuse. Encyclopédie Médico-Chirurgicale; Appareil Locomoteur. Dorfmann H ed.. Elsevier. 2012, 14-779
12. Toreson J, **Turcotte R.E**. Pathways to metastases: how do metastases develop in bone. In: Advances in Bone Metastasis Management. P Picci and P Ruggieri Eds. Future Medicine, Unitec House, London, 2012. www.futuremedicine.com

Josie Ursini-Siegel

1. **Josie Ursini-Siegel***, W. Rod Hardy, Yong Zheng, Dongmei Zuo, Lauren Podmore, Tony Pawson and William J. Muller. 2012 The ShcA SH2 domain activates a pro-survival response during mammary tumorigenesis. **Oncogene**, 31: 5038-5044
2. Vessela Kristensen*, Charles Vaske*, **Josie Ursini-Siegel**, Peter Van Loo, Ravi Sachidanandam , Therese Sørli , Fredrik Wärnberg , Vilde Haakensen , Aslaug Helland , Bjørn Naume , Charles Perou , David Haussler, Olga Troyanskaya and Anne-Lise Børresen-Dale. 2012. Integrated Molecular Profiles of Invasive Breast Tumors and DCISs Reveal Differential Vascular and Interleukin Signalling. **PNAS**, 109: 2802-7.

* co-first authors

Te Vuong

1. Hunter C, Garant A, Vuong T, Artho G, Abulafi M, Brown G, Adverse Features on Rectal MRI Identify a High-risk Group that May Benefit from More Intensive Preoperative Staging and Treatment, [Ann Surg Oncol](#). 19(4):1199-205, April 2012
2. Jakobsen A, Ploen J, Vuong T, Appelt A, Lindeberg J, Rafaelsen R. S, The dose-effect relationship in chemoradiation of locally advanced rectal cancer. A randomized trial comparing two radiation doses, *Int J Radiat Oncol Biol Phys*, Volume 84, Issue 4, Pages 950-954, November 2012
3. Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, Alcindor T, Vuong T, EGFR and K-ras gene mutation status in Squamous Cell Anal Carcinom.: A role for concurrent radiation and EGFR inhibitors? *Br J Cancer*, Vol 107, No 11, Pages 1864-1868, November 20 2012
4. Niazi, T Vuong T, Azoulay L, Marijnen C, Bujko K, Nasr E, Lambert C, Duclos M, Faria S, Cummings B. Silver Clear Nylon Dressing is Effective in Preventing Radiation Induced Dermatitis in Patients with Lower Gastrointestinal Cancer: Results from a phase III study, *Int J Radiat Oncol Biol Phys*, Vol. 84, Issue 3, Pages e305-310, November 1 2012
5. Hesselager C, Vuong T, Pahlman L, Liberman S, Letellier F, Folkesson J, Short term outcomes after neoadjuvant high dose rate endorectal brachytherapy versus short course external beam radiotherapy in resectable rectal cancer. Accepted, *Int J Colorectal Dis*.
6. Néron S, Perez S, Benc R, Bellman A, Holcroft C, Rosberger Z, **Vuong T**. The Pain and Anxiety Trajectory for Rectal Cancer Patients during Brachytherapy, Submitted to *Psycho-Oncology*
7. Néron S, Perez S, Benc R, Bellman A, Rosberger Z, **Vuong T**, Patients' Experience of Rectal High-Dose Rate (HDR) Brachytherapy Exploring the Inter-Subjectivity of Pain, (Submitted, December 17 2012)

Jian Hui Wu

1. #Liu, B.; Geng, G.Y.; Lin, R.T.; Ren, C.Y. and ***Wu, J.H.** Learning from estrogen receptor antagonism: Structure-based identification of novel antiandrogens effective against multiple clinically-relevant androgen receptor mutants. *Chem Biol & Drug Des*, 2012, 79:300-312.
2. #Weiguo Liu, #Jinming Zhou, Guoyan Geng, Qingwen Shi, Francoise Sauriol and ***Jian Hui Wu**. Antiandrogenic, maspin induction and anti-prostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A. *Journal of Medicinal Chemistry*, 2012, 55:971-975 (This journal ranks No. 1 in the field of Medicinal Chemistry).
3. Jeremy Hsieh, Moutih Rafei, Patrick Williams, Elena Birman, Jessica Cuerquis, **Jian Hui Wu** and *Jacques Galipeau. Inducible IL10/IL-4 suppressor B cells inhibit CNS inflammation and T helper 17 Polarization, *Molecular Therapy*, 2012, 20:1767-1777.
4. Krikor Bijian, Zhongwei Zhang, Bin Xu, Su Jie, Bo Chen, Shengbiao Wan, **Jian Hui Wu**, Tao Jiang and *Moulay Alaoui-Jamali. Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases. *Eur J Med Chem*, 2012, 48:143-152.

Maria Zannis-Hadjopoulos

1. Andersen, SD, Rampakakis, E., El-Shemerly, M., Luhn, P., Nielsen, FC., Du, YH., May, A., Bohr, V.A., Fu, H., Ferrari, S., **Zannis-Hadjopoulos, M.** and Rasmussen, LJ. (2012). DNA repair protein human exonuclease 1 (hEXO1) interacts with regulatory checkpoint proteins

14-3-3 - a novel protein interaction network between DNA repair and cell cycle control DNA Repair (*Amst*);11(3):267-77.

2. Di Paola, D., and **Zannis-Hadjopoulos, M.** (2012). Comparative analysis of pre-replication complex (pre-RC) proteins at replication origins of transformed and normal cells. *J. Cell. Biochem.*, 113:1333–1347.
3. Di Paola, D., Rampakakis, E., Chan, MK., **Zannis-Hadjopoulos M.** (2012). Differential chromatin structure encompassing replication origins in transformed and normal cells. *Genes & Cancer*, 3: 152-176.